

Caribbean Region

Country Operational Plan

FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	GAP	Funding Source GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
State		399,544		399,544	94,962	494,506
USAID		4,845,010	6,536,628	11,381,638	3,121,254	14,502,892
DOD		0		0	798,000	798,000
РС		0		0	119,587	119,587
HHS/CDC	1,593,750	6,798,711		8,392,461	2,766,696	11,159,157
HHS/HRSA		2,008,000		2,008,000	0	2,008,000
State/WHA		200,000		200,000	0	200,000
Total	1,593,750	14,251,265	6,536,628	22,381,643	6,900,499	29,282,142

Summary of Planned Funding by Budget Code and Agency

	Agency								
Budget Code	State	State/WHA	DOD	HHS/CDC	HHS/HRS A	PC	USAID	On Hold Amount	Total
НВНС			0	231,319	288,000		4,256,678	0	4,775,997
НКІД							105,688	0	105,688
HLAB			0	1,663,465				0	1,663,465
HTXS				616,480	1,669,935		906,707	0	3,193,122
НУСТ			0	187,745			782,506	0	970,251
HVMS	399,544		0	2,758,257		0	1,170,462	0	4,328,263
HVOP		200,000	0	89,329		0	1,439,708	0	1,729,037
HVSI	0		0	2,595,350			217,572	0	2,812,922
HVTB							0	0	0
мтст				0				0	0

Custom 2017-04-11 10:08 EDT



Approved

OHSS				172,898	50,065	0	2,502,317	0	2,725,280
PDCS				13,364				0	13,364
PDTX				64,254				0	64,254
	399,544	200,000	0	8,392,461	2,008,000	0	11,381,638	0	22,381,643



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	4,588,904	0
НКІД	97,193	0
PDCS	13,364	0
Total Technical Area Planned Funding:	4,699,461	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,368,681	0
HVSI	2,074,417	0
OHSS	2,556,456	0
Total Technical Area Planned Funding:	5,999,554	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	827,335	0
HVOP	1,565,368	0
МТСТ	0	
Total Technical Area Planned Funding:	2,392,703	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	3,093,638	0



PDTX	64,254	0
Total Technical Area Planned Funding:	3,157,892	0



Antigua and Barbuda



Bahamas

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	-
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	1,102
	that are based on evidence and/or	1,102
	meet the minimum standards	
	required	
	Total estimated number of key	
	population in the catchment area	4,409
KP_PREV_DSD	By key population type: Men who	
	have sex with men who are sex	
	workers (Numerator: Number of	
	key populations reached with	
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Men who	
	have sex with men who are NOT	
	sex workers (Numerator: Number	
	of key populations reached with	372
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	730
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
,· , ,	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	1,489
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	2,920
Total estimated number of key	2,020
rotal ostimated number of key	



	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	882
	their test results during the past 12	002
	months	
HTC_TST_TA	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	1.90,00A. 20 10 Maio	



Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	294
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	588
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	



and Sex: Positive <15 Male	
Test Result by Aggregated Age	10
and Sex: Positive 15+ Male	18
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	20
and Sex: Positive 15+ Female	30
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	



by Age: <15 other
Service Delivery Point (Facility): Inpatient
Service Delivery Point (Facility): Outpatient
Service Delivery Point (Facility): Pediatric
Service Delivery Point (Facility): Malnutrition facilities
Service Delivery Point (Facility): Other PITC
Service Delivery Point (Facility): VCT
Service Delivery Point (Facility): VMMC
Service Delivery Point (Facility): PMTCT
Service Delivery Point (Facility): TB Clinics
Service Delivery Point (Facility): Index testing
Service Delivery Point (Facility) by Age: <15 Inpatient
Service Delivery Point (Facility) by Age: >15 Inpatient
Service Delivery Point (Facility) by Age: <15 Outpatient
Service Delivery Point (Facility) by Age: >15 Outpatient
Service Delivery Point (Facility) by Age: <15 Pediatroc
Service Delivery Point (Facility) by Age: >15 Pediatroc
Service Delivery Point (Facility) by



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of adults and children	
	newly enrolled on antiretroviral	240
	therapy (ART)	
TX_NEW_TA	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
L	· · ·	



	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
E	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	114
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
l	Aggregated Grouping by Age/Sex: 1-14 Female	
L	Aggregated Grouping by Age/Sex: 15+ Female	126
S	Sum of Aggregated Age/Sex	240
1		



	disaggregates	
	Pregnancy status	
	Breastfeeding status	
	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	CD4: Number of laboratories that participate in this PT program	1
	CD4: Number of laboratories that perform this testing	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	4
	HIV serologic/diagnostic testing: Number of laboratories that	4



	perform this testing	
	HIV viral load: Number of	
	laboratories that achieve	1
	acceptable successful passing	I
	criteria in this PT program	
	HIV viral load: Number of	
	laboratories that participate in this	1
	PT program	
	HIV viral load: Number of	
	laboratories that perform this	1
	testing	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	4
	achieve acceptable successful	1
	passing criteria in this PT program	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	1
	participate in this PT program	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	1
	perform this testing	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	achieve acceptable successful	0
	passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	achieve acceptable successful	0
	passing criteria in this PT program	
	processing enteria in ano i i program	



	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	perform this testing	
	PEPFAR resources used for	
	HIV-program related commodities:	1,333
	planned & purchased in the last 12	1,000
	months by Implementing Partner	
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents	
	purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load	4 000
	Reagents purchased	1,333
	Number of HIV ARVs purchased	
INVS_COMD	Number of Second Line HIV ARVs	
	purchased	
	HIV Test Kits: Dollars planned	
	(COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned	
	(COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned	
	(COP)/ spent (Actual)	40,000
	Condoms: Dollars planned (COP)/	
	spent (Actual)	
	HIV ARVs: Dollars planned (COP)/	
	spent (Actual)	



Barbados

Indicator Number	Label	2017
	Number of adults and children	
	receiving antiretroviral therapy	1,578
	(ART)	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
TX_CURR_TA	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	899
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	679
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	1,578
	Sum of Aggregated Age/Sex	
	disaggregates	1,578



	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children	
	newly enrolled on antiretroviral	164
	therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
TX_NEW_DSD	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1	
	Male	
	Aggregated Grouping by Age/Sex:	



	<15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	82
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	82
	Sum of Aggregated Age/Sex disaggregates	164
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
TX_NEW_TA	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	



	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <a><15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	0
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <a><15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	6
	Sum of Aggregated Age/Sex disaggregates	6
	Pregnancy status	
	Breastfeeding status	
	TX_PVLS_TA Percentage of ART patients with a viral load result	
TX_PVLS_TA	documented in the medical record and/or laboratory information systems (LIS) within the past 12	n/a
	months with a suppressed viral load (<1000 copies/ml)	



Number of adults and pediatric patients on ART with suppress viral load results (<1,000 copie documented in the medical rec and /or supporting laboratory results within the past 12 mont	ed s/ml) ords
Number of adult and pediatric / patients with a viral load result documented in the patient med record and /or laboratory rec in the past 12 months.	ART lical 1,578
Numerator: Age/Sex by Indicat <1 Routine	
Numerator: Age/Sex by Indicat <1 Targeted	
Numerator: Age/Sex by Indicat 1-9 Routine	ion:
Numerator: Age/Sex by Indicat 1-9 Targeted	ion:
Numerator: Age/Sex by Indicat 10-14 Female Routine	ion:
Numerator: Age/Sex by Indicat 10-14 Female Targeted	ion:
Numerator: Age/Sex by Indicat 10-14 Male Routine	ion:
Numerator: Age/Sex by Indicat 10-14 Male Targeted	ion:
Numerator: Age/Sex by Indicat 15-19 Female Routine	ion:
Numerator: Age/Sex by Indicat 15-19 Female Targeted	ion:
Numerator: Age/Sex by Indicat 15-19 Male Routine	ion:
Numerator: Age/Sex by Indicat 15-19 Male Targeted	ion:



Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Targeted
Numerator: Age/Sex by Indication: 20-24 Male Routine
Numerator: Age/Sex by Indication: 20-24 Male Targeted
Numerator: Age/Sex by Indication: 25-49 Female Routine
Numerator: Age/Sex by Indication: 25-49 Female Targeted
Numerator: Age/Sex by Indication: 25-49 Male Routine
Numerator: Age/Sex by Indication: 25-49 Male Targeted
Numerator: Age/Sex by Indication: 50+ Female Routine
Numerator: Age/Sex by Indication: 50+ Female Targeted
Numerator: Age/Sex by Indication: 50+ Male Routine
Numerator: Age/Sex by Indication: 50+ Male Targeted
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine



Numerator: Aggregate Age/Sex by
Indication: 15+ Female Targeted
Numerator: Aggregate Age/Sex by
Indication: 15+ Male Routine
Numerator: Aggregate Age/Sex by
Indication: 15+ Male Targeted
Numerator: Indication: Routine
Numerator: Indication: Targeted
Numerator: Preg/BF by Indication:
Breastfeeding Routine
Numerator: Preg/BF by Indication:
Breastfeeding Targeted
Numerator: Preg/BF by Indication:
Pregnant Routine
Numerator: Preg/BF by Indication:
Pregnant Targeted
Denominator: Indication: Routine
Denominator: Indication: Targeted
Denominator: Age/Sex by
Indication: <1 Routine
Denominator: Age/Sex by
Indication: <1 Targeted
Denominator: Age/Sex by
Indication: 1-9 Routine
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 10-14 Female Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 10-14 Male Targeted



	1
Denominator: Age/Sex by	
Indication: 15-19 Female Routine	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Male Routine	
Denominator: Age/Sex by	
Indication: 15-19 Male Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Female Routine	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Male Routine	
Denominator: Age/Sex by	
Indication: 20-24 Male Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Female Routine	
Denominator: Age/Sex by	
Indication: 25-49 Female Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Male Routine	
Denominator: Age/Sex by	
Indication: 25-49 Male Targeted	
Denominator: Age/Sex by	
Indication: 50+ Female Routine	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Male Routine	
Denominator: Age/Sex by	
Indication: 50+ Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Routine	



1	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Targeted	
Denominator: Preg/BF by	
Indication: Breastfeeding Routine	
Denominator: Preg/BF by	
Indication: Breastfeeding Targeted	
Denominator: Preg/BF by	
Indication: Pregnant Routine	
Denominator: Preg/BF by	
Indication: Pregnant Targeted	
Numerator Aggregated Age/Sex:	
<15 Male	
Numerator Aggregated Age/Sex:	719
15+ Male	719
Numerator Aggregated Age/Sex:	
<15 Female	
Numerator Aggregated Age/Sex:	543
15+ Female	040
Denominator Aggregated Age/Sex:	
<15 Male	
Denominator Aggregated Age/Sex:	899
 15+ Male	033



	Denominator Aggregated Age/Sex:	
	<15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	679
	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	CD4: Number of laboratories that participate in this PT program	1
	CD4: Number of laboratories that perform this testing	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5
	HIV serologic/diagnostic testing:	5



Number of laboratories that	
perform this testing	
HIV viral load: Number of	
laboratories that achieve	1
acceptable successful passing	I
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	1
PT program	
HIV viral load: Number of	
laboratories that perform this	1
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	1
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	1
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	1
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	0
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	0
participate in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	0
perform this testing	
TB diagnostics (Culture/DST):	
Number of laboratories that	0
achieve acceptable successful	Ŭ



ſ		
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	perform this testing	
	PEPFAR resources used for	
	HIV-program related commodities:	500
	planned & purchased in the last 12	500
	months by Implementing Partner	
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents	
	purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load	
	Reagents purchased	500
	Number of HIV ARVs purchased	
INVS_COMD	Number of Second Line HIV ARVs	
	purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned	
	(COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned	25,000
	(COP)/ spent (Actual)	
	Condoms: Dollars planned (COP)/	
	spent (Actual)	
	HIV ARVs: Dollars planned (COP)/	
	spent (Actual)	



Belize - Caribbean

Approved



Technical Area Summary Indicators and Targets

Dominica

Approved



Technical Area Summary Indicators and Targets

Grenada



Guyana

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,652
	Total estimated number of key population in the catchment area	3,658
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	1,286



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	1 000
level HIV preventive interventions	1,366
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
n i i i i i i i i i i i i i i i i i i i	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	1,837
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
` number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	1 004
sex workers (FSW) (Denominator:	1,821
Total estimated number of key	



	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	4,607
	their test results during the past 12	4,007
	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	v	



Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex: Positive: 50+ Female
Test Result by Age and Sex: Negative: 10-14 Male
Test Result by Age and Sex: Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
, , , , , , , , , , , , , , , , , , , ,



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	83
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+ Male	2,019
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	73
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	2,432
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	_
and Sex: Positive <15 Male	6
Test Result by Aggregated Age	99



d Sex: Positive	15+ Male	
st Result by Age	gregated Age	4
d Sex: Positive	<15 Female	4
st Result by Age	gregated Age	101
d Sex: Positive	15+ Female	101
st Result by Age	e: Positive: <1	
st Result by Age	e: Positive: 1-9	
e/sex: <1		
e/sex: 1-9		
rvice Delivery P	Point	
ommunity): Inde	ex testing	150
rvice Delivery P		
-	nebased testing	
rvice Delivery P	Point	
ommunity): Mob		1,739
rvice Delivery P	Point	
ommunity): Othe	er	763
rvice Delivery P	Point (Community)	
Age: <15 index		
rvice Delivery P	Point (Community)	
Age: 15+ index	testing	
rvice Delivery P	Point (Community)	
Age: <15 home		
rvice Delivery P	Point (Community)	
Age: 15+ home	ebased testing	
rvice Delivery P	Point (Community)	
Age: <15 mobil	le testing	
rvice Delivery P	Point (Community)	
Age: 15+ mobil	le testing	
rvice Delivery P	Point (Community)	
Age: <15 other		
rvice Delivery P	Point (Community)	
Age: <15 other		
rvice Delivery P	Point (Facility):	



Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	1,655
Service Delivery Point (Facility): VCT	
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	300
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by	
Age: >15 Pediatroc	
Service Delivery Point (Facility) by	
Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by	



	۰ ۲	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of active beneficiaries	
	served by PEPFAR OVC programs	162
OVC_SERV_DSD	for children and families affected by	
	HIV/AIDS	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	52



Age/Sex: 10-14 Female	
Age/Sex: 15-17 Female	
By: Age/sex: 18-24 Female	
By: Age/sex: 25+ Female	
Age/Sex: 18+ Female	83
Sum of Age/Sex disaggregates	135
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female <1	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
25+	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male <1	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male 10-14	
Required only for DREAMS	
countries - By service, age and	
 sex: Education Support Male 15-17	



Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Female <1	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Female 10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Female 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Female 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Male <1	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Male 10-14	
Required only for DREAMS	



	es - By service, age and arenting/Caregiver Programs 5-17
Require countri sex: Pa	ed only for DREAMS es - By service, age and arenting/Caregiver Programs
	ed only for DREAMS
	es - By service, age and arenting/Caregiver Programs 5+
countri	ed only for DREAMS es - By service, age and
Requir	ed only for DREAMS es - By service, age and
sex: So 10-14	ocial Protection Female
countri	ed only for DREAMS es - By service, age and ocial Protection Female
countri	ed only for DREAMS es - By service, age and ocial Protection Female
countri	ed only for DREAMS es - By service, age and ocial Protection Female 25+
countri	ed only for DREAMS es - By service, age and ocial Protection Male <1
Require countri	ed only for DREAMS es - By service, age and ocial Protection Male 10-14



Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female <1	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
<1	
Required only for DREAMS	
countries - By service, age and	



sex: Economic Strengthening Male 10-14
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male
15-17
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24
Required only for DREAMS
countries - By service, age and
sex: Economic Strengthening Male
25+
Required only for DREAMS
countries - By service, age and
sex: Other Services Female <1
Required only for DREAMS
countries - By service, age and
sex: Other Services Female 10-14
Required only for DREAMS
countries - By service, age and
sex: Other Services Female 15-17
Required only for DREAMS
countries - By service, age and
sex: Other Services Female 18-24
Required only for DREAMS
countries - By service, age and
sex: Other Services Female 25+
Required only for DREAMS
countries - By service, age and
sex: Other Services Male <1
Required only for DREAMS
countries - By service, age and
sex: Other Services Male 10-14



Required only for DREAMS
countries - By service, age and
sex: Other Services Male 15-17
Required only for DREAMS
countries - By service, age and
sex: Other Services Male 18-24
Required only for DREAMS
countries - By service, age and
sex: Other Services Male 25+
Age/Sex: <1
Age/Sex: 1-9
Required only for DREAMS
countries - By service, age and
sex: Education Support 1-9 Male
Required only for DREAMS
countries - By service, age and
sex: Parenting/Caregiver Programs
Male 1-9
Required only for DREAMS
countries - By service, age and
sex: Social Protection Programs
Male 1-9
Required only for DREAMS
countries - By service, age and
sex: Economic Strengthening Male
1-9
Required only for DREAMS
countries - By service, age and
sex: Other Services Male 1-9
Program Completion: Active
Program Completion: Graduation
Program Completion: Transferred
Program Completion: Exited
 without graduation



	By Aggregated Age/Sex: <18 Male	12
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18	15
	Female	15
	By Aggregated Age/Sex: 18+	
	Female	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Education Support Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Parenting/Caregiver Programs	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Social Protection Programs	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Economic Strengthening	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Other Services Female 1-9	
	The number of PLHIV who were	
	screened for TB symptoms at the	1 740
	last clinical visit at a HIV facility	1,718
	during the reporting period.	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15	0
	Male	9
	Screened for TB by Age/Sex: 15+	
	Male	644
	Screened for TB by Age/Sex:<15	
	Female	35
	Screened for TB by Age/Sex: 15+	1,030
4	, ,	



	Female	
	Screen Result: Screened Positive for TB	35
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	35
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	27
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,861
	Screened for TB by Age/Sex: <15 Male	100
	Screened for TB by Age/Sex: 15+ Male	837
	Screened for TB by Age/Sex: <15 Female	94
	Screened for TB by Age/Sex: 15+ Female	830
	Screen Results: Screened Positive for TB	38
	TB Positive by Age/Sex: <15 Male	



	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15	
	Female	
	TB Positive by Age/Sex: 15+	
	Female	
	[Sub-Disagg of Screen Results]	
	Specimen Sent: Specimen sent for	38
	bacteriologic diagnosis of active TB	
	[Sub-disagg of Specimen Sent]	
	Diagnostic Test: Smear Only	29
	[Sub-disagg of Specimen Sent]	
	Diagnostic Test: Xpert MTB/RIF	9
	assay	-
	[Sub-disagg of Specimen Sent]	
	Diagnostic Test: Other (Not Xpert)	
	PMTCT_EID_TA Percent of infants	
	born to HIV-positive women that	
	receive a virological HIV test within	n/a
	12 months of birth (TA)	
	Number of infants who had a	
	virologic HIV test within 12 months	
	of birth during the reporting period	
	Number of HIV- positive pregnant	
	women identified during the	
	reporting period (include known	
PMTCT_EID_TA	HIV-positive women at entry into	
	PMTCT)	
	By infants who received a virologic	
	test within 2 months of birth	38
	By infants who received their first	
	virologic HIV test between 2 and 12	2
	months of age	-
	Sum of Infant Age disaggregates	40
	By infants with a positive virologic test result within 12 months of birth	



		1
	Number of infants with a positive	
	virological test result within 2	0
	months of birth	
	Number of infants with a negative	
	virological test result within 2	
	months of birth	
	Number of infants with a positive	
	virological test result between 2	
	and 12 months of birth	
	Number of infants with a negative	
	virological test result between 2	
	and 12 months of birth	
	Number of infants with a positive	
	virological test result within 12	0
	months of birth	
	Number of adults and children	
	receiving antiretroviral therapy	1,718
	(ART)	
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	9
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	644
	Aggregated Age/Sex: <15 Female	35
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,030
	Sum of Aggregated Age/Sex <15	44
	Sum of Aggregated Age/Sex 15+	1,674
	Sum of Aggregated Age/Sex	·
	disaggregates	1,718
	Age/Sex: <1	
	Age/Sex: <1-9	
	nye/0er. <1-3	



	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children	
	receiving antiretroviral therapy	1,861
	(ART)	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
TX_CURR_TA	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	94
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	830
	Aggregated Age/Sex: <15 Female	100
	Aggregated Age/Sex: 1-14 Female	



	Aggregated Age/Sex: 15+ Female	837
	Sum of Aggregated Age/Sex <15	194
	Sum of Aggregated Age/Sex 15+	1,667
	Sum of Aggregated Age/Sex disaggregates	1,861
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	322
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
TX_NEW_DSD	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	



	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	147
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2
	Aggregated Grouping by Age/Sex: 15+ Female	171
	Sum of Aggregated Age/Sex disaggregates	322
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	349
	By Age/Sex: <1	
	By Age/Sex: 1-9	
TX_NEW_TA	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	163
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	182
	Sum of Aggregated Age/Sex disaggregates	349
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of	n/a



i I	
ART patients with a viral load result	
documented in the medical record	
and/or laboratory information	
systems (LIS) within the past 12	
months with a suppressed viral	
load (<1000 copies/ml)	
Number of adults and pediatric	
patients on ART with suppressed	
viral load results (<1,000 copies/ml)	
documented in the medical records	1,160
and /or supporting laboratory	
results within the past 12 months.	
Number of adult and pediatric ART	
patients with a viral load result	
documented in the patient medical	1,546
record and /or laboratory records	,
in the past 12 months.	
Numerator: Indication: Routine	1,160
Numerator: Indication: Targeted	
Numerator: Preg/BF by Indication:	
Pregnant Routine	
Numerator: Preg/BF by Indication:	
Breastfeeding Routine	
Numerator: Preg/BF by Indication:	
Pregnant Targeted	
Numerator: Preg/BF by Indication:	
Breastfeeding Targeted	
Numerator: Age/Sex by Indication:	
<1 Routine	
Numerator: Age/Sex by Indication:	
1-9 Routine	
Numerator: Age/Sex by Indication:	
10-14 Male Routine	
Numerator: Age/Sex by Indication:	
15-19 Male Routine	



Numerator: Age/Sex by Indication: 20-24 Male Routine
Numerator: Age/Sex by Indication: 25-49 Male Routine
Numerator: Age/Sex by Indication: 50+ Male Routine
Numerator: Age/Sex by Indication: 10-14 Female Routine
Numerator: Age/Sex by Indication: 15-19 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 25-49 Female Routine
Numerator: Age/Sex by Indication: 50+ Female Routine
Numerator: Age/Sex by Indication: <1 Targeted
Numerator: Age/Sex by Indication: 1-9 Targeted
Numerator: Age/Sex by Indication: 10-14 Male Targeted
Numerator: Age/Sex by Indication: 15-19 Male Targeted
Numerator: Age/Sex by Indication: 20-24 Male Targeted
Numerator: Age/Sex by Indication: 25-49 Male Targeted
Numerator: Age/Sex by Indication: 50+ Male Targeted
Numerator: Age/Sex by Indication: 10-14 Female Targeted
Numerator: Age/Sex by Indication: 15-19 Female Targeted



Numerator: Age/Sex by Indication: 20-24 Female Targeted	
Numerator: Age/Sex by Indication: 25-49 Female Targeted	
Numerator: Age/Sex by Indication:	
50+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	
Denominator: Indication: Routine	1,546
Denominator: Indication: Targeted	
Denominator: Preg/BF by	
Indication: Pregnant Routine	
Denominator: Preg/BF by	
Indication: Breastfeeding Routine	
Denominator: Preg/BF by	
Indication: Pregnant Targeted	
Denominator: Preg/BF by	
Indication: Breastfeeding Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	



Denominator: Age/Sex by
Indication: 1-9 Routine
Denominator: Age/Sex by
Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: <1 Targeted
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Targeted



Denominator: Age/Sex by	
Indication: 50+ Male Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Routine	
Numerator Aggregated Age/Sex:	20
<15 Male	29
Numerator Aggregated Age/Sex:	540
15+ Male	543
Numerator Aggregated Age/Sex:	20
 <15 Female	29



	Numerator Aggregated Age/Sex: 15+ Female	559
	Denominator Aggregated Age/Sex: <15 Male	38
	Denominator Aggregated Age/Sex: 15+ Male	715
	Denominator Aggregated Age/Sex: <15 Female	40
	Denominator Aggregated Age/Sex: 15+ Female	753
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
TX PVLS TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,256
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,675
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication:	



1-9 Targeted
Numerator: Age/Sex by Indication:
10-14 Female Routine
Numerator: Age/Sex by Indication: 10-14 Female Targeted
Numerator: Age/Sex by Indication: 10-14 Male Routine
Numerator: Age/Sex by Indication: 10-14 Male Targeted
Numerator: Age/Sex by Indication: 15-19 Female Routine
Numerator: Age/Sex by Indication:
15-19 Female Targeted
Numerator: Age/Sex by Indication:
15-19 Male Routine
Numerator: Age/Sex by Indication:
15-19 Male Targeted
Numerator: Age/Sex by Indication:
20-24 Female Routine
Numerator: Age/Sex by Indication:
20-24 Female Targeted
Numerator: Age/Sex by Indication:
20-24 Male Routine
Numerator: Age/Sex by Indication:
20-24 Male Targeted
Numerator: Age/Sex by Indication:
25-49 Female Routine
Numerator: Age/Sex by Indication:
25-49 Female Targeted
Numerator: Age/Sex by Indication:
25-49 Male Routine
Numerator: Age/Sex by Indication:
25-49 Male Targeted
Numerator: Age/Sex by Indication:



50+ Female Routine Numerator: Age/Sex by Indication: 50+ Female Targeted Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Indication: Routine Numerator: Indication: Routine Numerator: Preg/BF by Indication:	Numerator: Age/Sex by Indication:50+ Female TargetedNumerator: Age/Sex by Indication:50+ Male RoutineNumerator: Age/Sex by Indication:50+ Male TargetedNumerator: Aggregate Age/Sex byIndication: <15 Female Routine	
50+ Female Targeted Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	50+ Female Targeted Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
50+ Male Routine Numerator: Age/Sex by Indication: S0+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
Numerator: Age/Sex by Indication:50+ Male TargetedNumerator: Aggregate Age/Sex byIndication: <15 Female Routine	Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
Indication: <15 Female Routine Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted		
Indication: <15 Female Targeted Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:		
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	Numerator: Aggregate Age/Sex by	
Indication: <15 Male Routine	Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	Numerator: Aggregate Age/Sex by	
Indication: <15 Male Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Indication: Routine 1,256 Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Numerator: Aggregate Age/Sex by	
Indication: 15+ Female TargetedNumerator: Aggregate Age/Sex byIndication: 15+ Male RoutineNumerator: Aggregate Age/Sex byIndication: 15+ Male TargetedNumerator: 15+ Male TargetedNumerator: Indication: Routine1,256Numerator: Indication: TargetedNumerator: Preg/BF by Indication:Breastfeeding RoutineNumerator: Preg/BF by Indication:Breastfeeding TargetedNumerator: Preg/BF by Indication:Breastfeeding TargetedNumerator: Preg/BF by Indication:Pregnant RoutineNumerator: Preg/BF by Indication:	Indication: 15+ Female Routine	
Numerator: Aggregate Age/Sex by Indication: 15+ Male RoutineNumerator: Aggregate Age/Sex by Indication: 15+ Male TargetedNumerator: Indication: Routine1,256Numerator: Indication: TargetedNumerator: Preg/BF by Indication: Breastfeeding RoutineNumerator: Preg/BF by Indication: Breastfeeding TargetedNumerator: Preg/BF by Indication: Pregnant RoutineNumerator: Preg/BF by Indication: Pregnant RoutineNumerator: Preg/BF by Indication:	Numerator: Aggregate Age/Sex by	
Indication: 15+ Male RoutineNumerator: Aggregate Age/Sex byIndication: 15+ Male TargetedNumerator: Indication: Routine1,256Numerator: Indication: TargetedNumerator: Preg/BF by Indication:Breastfeeding RoutineNumerator: Preg/BF by Indication:Breastfeeding TargetedNumerator: Preg/BF by Indication:Pregnant RoutineNumerator: Preg/BF by Indication:	Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Male TargetedNumerator: 1ndication: Routine1,256Numerator: Indication: Targeted1Numerator: Preg/BF by Indication: Breastfeeding Routine1Numerator: Preg/BF by Indication: Breastfeeding Targeted1Numerator: Preg/BF by Indication: Breastfeeding Targeted1Numerator: Preg/BF by Indication: Breastfeeding Targeted1Numerator: Preg/BF by Indication: Pregnant Routine1Numerator: Preg/BF by Indication:1Numerator: Preg/BF by Indication:1Numerator: Preg/BF by Indication:1Pregnant Routine1Numerator: Preg/BF by Indication:1Numerator: Preg/BF by Indication:1	Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Indication: 15+ Male Routine	
Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted 1,256 Numerator: Preg/BF by Indication: 1,256 Breastfeeding Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Breastfeeding Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Breastfeeding Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Pregnant Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Pregnant Routine 1,256 Numerator: Preg/BF by Indication: 1,256	Numerator: Aggregate Age/Sex by	
Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Indication: 15+ Male Targeted	
Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Numerator: Indication: Routine 1,256	
Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Numerator: Indication: Targeted	
Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Numerator: Preg/BF by Indication:	
Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Breastfeeding Routine	
Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication:	Numerator: Preg/BF by Indication:	
Pregnant Routine Numerator: Preg/BF by Indication:	Breastfeeding Targeted	
Numerator: Preg/BF by Indication:	Numerator: Preg/BF by Indication:	
	Pregnant Routine	
Pregnant Targeted	Numerator: Preg/BF by Indication:	
	Pregnant Targeted	
Denominator: Indication: Routine 1,675		



Denominator: Indication: Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: <1 Targeted	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
Denominator: Age/Sex by	
Indication: 1-9 Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Female Routine	
Denominator: Age/Sex by	
Indication: 10-14 Female Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Male Routine	
Denominator: Age/Sex by	
Indication: 10-14 Male Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Female Routine	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Male Routine	
Denominator: Age/Sex by	
Indication: 15-19 Male Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Female Routine	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Male Routine	
Denominator: Age/Sex by	
Indication: 20-24 Male Targeted	
Denominator: Age/Sex by	



Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Targeted
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Female Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Female Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Male Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Male Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Targeted
Denominator: Preg/BF by
Indication: Breastfeeding Routine
Denominator: Preg/BF by



	Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by	
	Indication: Pregnant Routine	
	Denominator: Preg/BF by	
	Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	51
	Numerator Aggregated Age/Sex: 15+ Male	549
	Numerator Aggregated Age/Sex: <15 Female	73
	Numerator Aggregated Age/Sex: 15+ Female	583
	Denominator Aggregated Age/Sex: <15 Male	77
	Denominator Aggregated Age/Sex: 15+ Male	745
	Denominator Aggregated Age/Sex: <15 Female	91
	Denominator Aggregated Age/Sex: 15+ Female	762
	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	151
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	
	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	178



1	
Age/Sex: <1 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART	
Age/Sex: 1-9 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART	
Age/Sex: 10-14 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sed: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
13	



children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 51 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART, in the 12 months prior to the beginning of the reporting period,	
initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >10 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	children who are still alive and on
Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the adults and children who initiated ART in the 12 months prior	treatment at 12 months after
(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	initiating ART
children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those bots to stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	Age/Sex: 20-24 Female
treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	(Numerator: Number of adults and
initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior	children who are still alive and on
Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >0+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the begin have begin be available and children who initiated ART in the 12 months prior	treatment at 12 months after
Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >0 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior	initiating ART
children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	Age/Sex: 25-49 Female
treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	(Numerator: Number of adults and
initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	children who are still alive and on
Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	treatment at 12 months after
Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	initiating ART
are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	Age/Sex: 50+ Female (Numerator:
12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	Number of adults and children who
Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	are still alive and on treatment at
number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	12 months after initiating ART
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	Age/Sex: >1 (Denominator: Total
to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	number of adults and children who
period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	initiated ART in the 12 months prior
died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	to the beginning of the reporting
ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	period, including those who have
Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	died, those who have stopped
number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	ART, and those lost to follow-up)
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	Age/Sex: 1-9 (Denominator: Total
to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	number of adults and children who
period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	initiated ART in the 12 months prior
died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	to the beginning of the reporting
ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	period, including those who have
Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	died, those who have stopped
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	ART, and those lost to follow-up)
adults and children who initiated ART in the 12 months prior to the	Age/Sex: 10-14 Male
ART in the 12 months prior to the	(Denominator: Total number of
	adults and children who initiated
beginning of the reporting period,	ART in the 12 months prior to the
	beginning of the reporting period,



including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Male (Denominator:	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	
reporting period, including those	
who have died, those who have	
stopped ART, and those lost to	
follow-up)	
Age/Sex: 10-14 Female	



(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 15-19 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,



including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	
Numerator by Status:	
Breastfeeding	
Denominator by Status: Pregnant	
Denominator by Status:	
Breastfeeding	
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	7



]
children who are still alive and on treatment at 12 months after initiating ART)	
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76
Aggregated Age/Sex: <15 Female (Denominator: Total number of	10



adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	
including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	
those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	
those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, 84	
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	
ART in the 12 months prior to the 84 beginning of the reporting period,	
beginning of the reporting period,	
beginning of the reporting period,	
including those who have died	
those who have stopped ART, and	
those lost to follow-up)	
TX_RET_TA Percent of adults and	
children known to be alive and on	
treatment 12 months after initiation	
of antiretroviral therapy	
Number of adults and children who	
are still alive and on treatment at 200	
12 months after initiating ART	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	
reporting period, including those 227	
TX_RET_TA who have died, those who have	
stopped ART, and those lost to	
follow-up	
Age/Sex: <1 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART)	
Age/Sex: 1-9 (Numerator: Number	
Age/Sex: 1-9 (Numerator: Number	



Age/Sex: 10-14 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	



1	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 50+ Female (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: <1 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 1-9 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	



L	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Male (Denominator:	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	
reporting period, including those	
who have died, those who have	
stopped ART, and those lost to	
follow-up)	
Age/Sex: 10-14 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Female	



(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Aggregated Age: <15 (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Aggregated Age: 15+ (Numerator:



Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on 10 treatment at 12 months after<		
12 months after initiating ART) Aggregated Age: <15	Number of adults and children who	
Aggregated Age: <15	are still alive and on treatment at	
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	12 months after initiating ART)	
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after Numerator: Number of adults and children who are still alive and on treatment at 12 months after	Aggregated Age: <15	
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: BreastfeedingDenominator by Status: BreastfeedingDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	(Denominator: Total number of	
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	adults and children who initiated	
including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	ART in the 12 months prior to the	
those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	beginning of the reporting period,	
those lost to follow-up)Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantDenominator by Status: PregnantDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	including those who have died,	
Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantDenominator by Status: PregnantDenominator by Status: BreastfeedingDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	those who have stopped ART, and	
Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantDenominator by Status: PregnantDenominator by Status: BreastfeedingDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	those lost to follow-up)	
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	Aggregated Age: 15+	
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: BreastfeedingDenominator by Status: PregnantDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on 86 treatment at 12 months after	(Denominator: Total number of	
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantNumerator by Status: BreastfeedingDenominator by Status: PregnantDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male status: Aggregated Age/Sex: 15+ Male st	adults and children who initiated	
including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	ART in the 12 months prior to the	
those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status:BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterInitiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	beginning of the reporting period,	
those lost to follow-up)Numerator by Status: PregnantNumerator by Status:BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male	including those who have died,	
Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	those who have stopped ART, and	
Numerator by Status:BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	those lost to follow-up)	
BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	Numerator by Status: Pregnant	
Denominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	Numerator by Status:	
Denominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	Breastfeeding	
BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	Denominator by Status: Pregnant	
Aggregated Age/Sex: <15 Male(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86	Denominator by Status:	
(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86	Breastfeeding	
(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86	Aggregated Age/Sex: <15 Male	
children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86		
initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on 86 treatment at 12 months after		10
Aggregated Age/Sex: 15+ Male(Numerator: Number of adults and children who are still alive and on86treatment at 12 months after86	treatment at 12 months after	
(Numerator: Number of adults and children who are still alive and on 86 treatment at 12 months after	initiating ART)	
children who are still alive and on 86 treatment at 12 months after	Aggregated Age/Sex: 15+ Male	
treatment at 12 months after	(Numerator: Number of adults and	
	children who are still alive and on	86
initiating ART)	treatment at 12 months after	
	initiating ART)	



Aggregated Age/Sex: <15 Female	
(Numerator: Number of adults and	
children who are still alive and on	10
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Female	
(Numerator: Number of adults and	
children who are still alive and on	94
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	9
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	95
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: <15 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	14
beginning of the reporting period,	14
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Female	
(Denominator: Total number of	109



adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	



Technical Area Summary Indicators and Targets

Jamaica

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	2.095
	that are based on evidence and/or	2,085
	meet the minimum standards	
	required	
	Total estimated number of key	32,371
	population in the catchment area	52,571
KP_PREV_DSD	By key population type: Men who	
	have sex with men who are sex	
	workers (Numerator: Number of	
	key populations reached with	
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Men who	
	have sex with men who are NOT	
	sex workers (Numerator: Number	
	of key populations reached with	1,268
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	o / =
level HIV preventive interventions	817
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	18,754
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	13,617
Total estimated number of key	- ,
/	



		I
	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	KP_PREV_TA Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
KP_PREV_TA	based on evidence and/or meet the	
	minimum standards required	
	(TA-only)	
	Number of key populations reached	
	with individual and/or small group	118
J.		



level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required	
Total estimated number of key	
population in the catchment area	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	



(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who	
have sex with men and are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	118
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
rey populations reached with	



individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Denominator: Total	376
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Denominator: Total estimated	
 number of key population in the	



	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was	
	referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,859
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
HTC_TST_DSD	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	



Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male
Test Result by Age and Sex:
Negative: 10-14 Female
Test Result by Age and Sex:
Negative: 15-19 Female
Test Result by Age and Sex:
Negative: 20-24 Female
Test Result by Age and Sex:
Negative: 25-49 Female
Test Result by Age and Sex:
Negative: 50+ Female



Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ 735 Female
Test Result by Aggregated Age and Sex: Negative <15 Male
Test Result by Aggregated Age and Sex: Negative 15+ Male
Test Result by Aggregated Age and Sex: Negative <15 Female
Test Result by Aggregated Age and Sex: Negative 15+ Female
Test Result by Aggregated Age and Sex: Positive <15 Male
Test Result by Aggregated Age 120 and Sex: Positive 15+ Male 120
Test Result by Aggregated Age and Sex: Positive <15 Female
Test Result by Aggregated Age 22 and Sex: Positive 15+ Female 22
Test Result by Age: Positive: <1
Test Result by Age: Positive: 1-9
Age/sex: <1
Age/sex: 1-9
Service Delivery Point (Community): Index testing
Service Delivery Point (Community): Homebased testing



Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point (Community): Other	1,799
Service Delivery Point (Community) by Age: <15 index testing	
Service Delivery Point (Community) by Age: 15+ index testing	
Service Delivery Point (Community) by Age: <15 homebased testing	
Service Delivery Point (Community) by Age: 15+ homebased testing	
Service Delivery Point (Community) by Age: <15 mobile testing	
Service Delivery Point (Community) by Age: 15+ mobile testing	
Service Delivery Point (Community) by Age: <15 other	
Service Delivery Point (Community) by Age: <15 other	
Service Delivery Point (Facility): Inpatient	
Service Delivery Point (Facility): Outpatient	
Service Delivery Point (Facility): Pediatric	
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	
Service Delivery Point (Facility): VMMC	



Service Delivery Point (Facility): PMTCT
Service Delivery Point (Facility): TB Clinics
Service Delivery Point (Facility): Index testing
Service Delivery Point (Facility) by Age: <15 Inpatient
Service Delivery Point (Facility) by Age: >15 Inpatient
Service Delivery Point (Facility) by Age: <15 Outpatient
Service Delivery Point (Facility) by Age: >15 Outpatient
Service Delivery Point (Facility) by Age: <15 Pediatroc
Service Delivery Point (Facility) by Age: >15 Pediatroc
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities
Service Delivery Point (Facility) by Age: <15 Other PITC
Service Delivery Point (Facility) by Age: >15 Other PITC
Service Delivery Point (Facility) by Age: <15 VCT
Service Delivery Point (Facility) by Age: >15 VCT
Service Delivery Point (Facility) by Age: <15 VMMC
Service Delivery Point (Facility) by Age: >15 VMMC



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	94
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
HTC_TST_TA	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex:	
	Positive: 10-14 Male	
	Test Result by Age and Sex:	
	Positive: 15-19 Male	
	Test Result by Age and Sex:	



Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male
Test Result by Age and Sex:
Negative: <1 Female
Test Result by Age and Sex:
Negative: 10-14 Female
Test Result by Age and Sex:
Negative: 15-19 Female
Test Result by Age and Sex:
Negative: 20-24 Female
Test Result by Age and Sex:



Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	94
HQ PERMISSION ONLY: 15+ Male	94
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	
Test Result by Aggregated Age	14
and Sex: Positive 15+ Male	
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	
and Sex: Positive 15+ Female	
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	



(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	14
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	



VCT
Service Delivery Point (Facility): VMMC
Service Delivery Point (Facility): PMTCT
Service Delivery Point (Facility): TB Clinics
Service Delivery Point (Facility): Index testing
Service Delivery Point (Facility) by Age: <15 Inpatient
Service Delivery Point (Facility) by Age: >15 Inpatient
Service Delivery Point (Facility) by Age: <15 Outpatient
Service Delivery Point (Facility) by Age: >15 Outpatient
Service Delivery Point (Facility) by Age: <15 Pediatroc
Service Delivery Point (Facility) by Age: >15 Pediatroc
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities
Service Delivery Point (Facility) by Age: <15 Other PITC
Service Delivery Point (Facility) by Age: >15 Other PITC
Service Delivery Point (Facility) by Age: <15 VCT
Service Delivery Point (Facility) by Age: >15 VCT
Service Delivery Point (Facility) by



	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC Service Delivery Point (Facility) by	
	Age: <15 PMTCT Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	Number of adults and children receiving antiretroviral therapy	12,728
	(ART)	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
TX_CURR_TA	Age/Sex: <1 Female	
TA_CORK_TA	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	



	Aggregated Age/Sex: 15+ Male	6,109
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	6,620
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	12,729
	Sum of Aggregated Age/Sex	10 - 00
	disaggregates	12,729
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children	
	newly enrolled on antiretroviral	1,220
	therapy (ART)	
	By Age/Sex: <1	
TX_NEW_DSD	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	



	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <a><15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	585
	Aggregated Grouping by Age/Sex: <pre><1 Female</pre>	
	Aggregated Grouping by Age/Sex: <a><15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	635
	Sum of Aggregated Age/Sex disaggregates	1,220
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,217
TX_NEW_TA	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	



E	By Age/Sex: 10-14 Male	
E	By Age/Sex: 15-19 Male	
E	By Age/Sex: 20-24 Male	
E	By Age/Sex: 25-49 Male	
E	By Age/Sex: 50+ Male	
E	By Age/Sex: <1 Female	
E	By Age/Sex: 1-4 Female	
E	By Age/Sex: 5-9 Female	
E	By Age/Sex: 10-14 Female	
E	By Age/Sex: 15-19 Female	
E	By Age/Sex: 20-24 Female	
E	By Age/Sex: 25-49 Female	
E	By Age/Sex: 50+ Female	
S	Sum of Age/Sex disaggregates	
Α	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	80
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,034
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	26
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,083
	Sum of Aggregated Age/Sex lisaggregates	2,223



	Pregnancy status	
	Breastfeeding status	
	TX_PVLS_TA Percentage of ART	
	patients with a viral load result	
	documented in the medical record	
	and/or laboratory information	n/a
	systems (LIS) within the past 12	
	months with a suppressed viral	
	load (<1000 copies/ml)	
	Number of adults and pediatric	
	patients on ART with suppressed	
	viral load results (<1,000 copies/ml)	10,181
	documented in the medical records	10,101
	and /or supporting laboratory	
	results within the past 12 months.	
	Number of adult and pediatric ART	
	patients with a viral load result	
	documented in the patient medical	12,728
TX_PVLS_TA	record and /or laboratory records	
	in the past 12 months.	
	Numerator: Age/Sex by Indication:	
	<1 Routine	
	Numerator: Age/Sex by Indication:	
	<1 Targeted	
	Numerator: Age/Sex by Indication:	
	1-9 Routine	
	Numerator: Age/Sex by Indication:	
	1-9 Targeted	
	Numerator: Age/Sex by Indication:	
	10-14 Female Routine	
	Numerator: Age/Sex by Indication:	
	10-14 Female Targeted	
	Numerator: Age/Sex by Indication:	
	10-14 Male Routine	
	Numerator: Age/Sex by Indication:	



10-14 Male Targeted	
Numerator: Age/Sex by Indication:	
15-19 Female Routine	
Numerator: Age/Sex by Indication:	
15-19 Female Targeted	
Numerator: Age/Sex by Indication:	
15-19 Male Routine	
Numerator: Age/Sex by Indication:	
15-19 Male Targeted	
Numerator: Age/Sex by Indication:	
20-24 Female Routine	
Numerator: Age/Sex by Indication:	
20-24 Female Targeted	
Numerator: Age/Sex by Indication:	
20-24 Male Routine	
Numerator: Age/Sex by Indication:	
20-24 Male Targeted	
Numerator: Age/Sex by Indication:	
25-49 Female Routine	
Numerator: Age/Sex by Indication:	
25-49 Female Targeted	
Numerator: Age/Sex by Indication:	
25-49 Male Routine	
Numerator: Age/Sex by Indication:	
25-49 Male Targeted	
Numerator: Age/Sex by Indication:	
50+ Female Routine	
Numerator: Age/Sex by Indication:	
50+ Female Targeted	
Numerator: Age/Sex by Indication:	
50+ Male Routine	
Numerator: Age/Sex by Indication:	
50+ Male Targeted	
Numerator: Aggregate Age/Sex by	



1	
Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Indication: Routine	
Numerator: Indication: Targeted	
Numerator: Preg/BF by Indication:	
Breastfeeding Routine	
Numerator: Preg/BF by Indication:	
Breastfeeding Targeted	
Numerator: Preg/BF by Indication:	
Pregnant Routine	
Numerator: Preg/BF by Indication:	
Pregnant Targeted	
Denominator: Indication: Routine	
Denominator: Indication: Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: <1 Targeted	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
 Denominator: Age/Sex by	



Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 10-14 Female Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by



Indication: 50+ Female Routine	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Male Routine	
Denominator: Age/Sex by	
Indication: 50+ Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Targeted	
Denominator: Preg/BF by	
Indication: Breastfeeding Routine	
Denominator: Preg/BF by	
Indication: Breastfeeding Targeted	
Denominator: Preg/BF by	
Indication: Pregnant Routine	
Denominator: Preg/BF by	
Indication: Pregnant Targeted	
Numerator Aggregated Age/Sex:	
<15 Male	
 Numerator Aggregated Age/Sex:	4,886



	15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	5,295
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	6,109
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	6,619
	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an	
	analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	CD4: Number of laboratories that participate in this PT program	4
LAB_PT_TA	CD4: Number of laboratories that perform this testing	4
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this	1



testing		
	ogic/diagnostic testing:	
	of laboratories that	
	cceptable successful	18
	riteria in this PT program	
	ogic/diagnostic testing:	
	of laboratories that	18
	e in this PT program	
	ogic/diagnostic testing:	
	of laboratories that	18
	his testing	
·	load: Number of	
	es that achieve	
	le successful passing	1
-	this PT program	
	load: Number of	
	es that participate in this	1
PT progra		
	load: Number of	
	es that perform this	1
testing		
TB diagn	ostics (AFB microscopy):	
Number o	of laboratories that	C
achieve a	cceptable successful	6
passing c	riteria in this PT program	
TB diagn	ostics (AFB microscopy):	
Number o	of laboratories that	6
participat	e in this PT program	
TB diagn	ostics (AFB microscopy):	
Number o	of laboratories that	6
perform t	his testing	
TB diagn	ostics (Xpert MTB/RIF):	
Number o	of laboratories that	0
achieve a	cceptable successful	0
passing c	riteria in this PT program	



	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	achieve acceptable successful	0
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	perform this testing	
HRH_PRE	Number of new HCW who	
	graduated from a pre-service	
	training institution or program as a	6
	result of PEPFAR-supported	U
	strengthening efforts, within the	
	reporting period, by select cadre	
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service	
	workers	
	By Graduates: Laboratory	
	professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
	PEPFAR resources used for	
INVS_COMD	HIV-program related commodities:	
	planned & purchased in the last 12	6,299
	months by Implementing Partner	



Number of LUV/ Test Kite numbers of	1 000
Number of HIV Test Kits purchased	1,889
Number of HIV CD4 Reagents	
purchased	
Number of Condoms purchased	
Number of HIV Viral Load	0.007
Reagents purchased	3,067
Number of HIV ARVs purchased	1,343
Number of Second Line HIV ARVs	
purchased	
HIV Test Kits: Dollars planned	10.400
(COP)/ spent (Actual)	10,198
HIV CD4 Tests: Dollars planned	50.000
(COP)/ spent (Actual)	50,000
HIV Viral Load: Dollars planned	400 500
(COP)/ spent (Actual)	130,580
Condoms: Dollars planned (COP)/	
spent (Actual)	
HIV ARVs: Dollars planned (COP)/	
spent (Actual)	161,160



Technical Area Summary Indicators and Targets

St. Kitts and Nevis

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

St. Lucia

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

St. Vincent and the Grenadines

(No data provided.)



Technical Area Summary Indicators and Targets

Suriname

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	n/a
	minimum standards required (DSD) Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,345
	Total estimated number of key population in the catchment area	9,260
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	595



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	750
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
· · · · · · · · · · · · · · · · · · ·	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	6,800
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	2,460
Total estimated number of key	
•	



	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	` number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	255
	their test results during the past 12 months	
HTC_TST_DSD	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



Age/sex:50+ MaleAge/sex:5-9 FemaleAge/sex:10-14 FemaleAge/sex:10-14 FemaleAge/sex:20-24 FemaleAge/sex:20-24 FemaleAge/sex:50+ FemaleAge/sex:50+ FemaleTest Result by Age and Sex:Positive:Positive:10-14 MaleTest Result by Age and Sex:Positive:Positive:15-19 MaleTest Result by Age and Sex:Positive:Positive:20-24 Male	
Age/sex: 10-14 FemaleAge/sex: 15-19 FemaleAge/sex: 20-24 FemaleAge/sex: 20-24 FemaleAge/sex: 25-49 FemaleAge/sex: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 20-24 Male	
Age/sex: 15-19 FemaleAge/sex: 20-24 FemaleAge/sex: 25-49 FemaleAge/sex: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 20-24 Male	
Age/sex: 20-24 Female Age/sex: 25-49 Female Age/sex: 50+ Female Test Result by Age and Sex: Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male	
Age/sex: 25-49 FemaleAge/sex: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 20-24 Male	
Age/sex: 50+ Female Test Result by Age and Sex: Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male	
Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male	
Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male	
Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 20-24 Male	
Positive: 20-24 Male	l
Test Result by Age and Sex:	
Positive: 25-49 Male	
Test Result by Age and Sex:	
Positive: 50+ Male	
Test Result by Age and Sex:	
Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex:	
Positive: 20-24 Female	
Test Result by Age and Sex:	
Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex:	
Negative: 15-19 Male	
Test Result by Age and Sex:	
Negative: 20-24 Male	
Test Result by Age and Sex:	



N	legative: 25-49 Male	
	est Result by Age and Sex:	
	legative: 50+ Male	
Т	est Result by Age and Sex:	
N	legative: 10-14 Female	
	est Result by Age and Sex:	
N	legative: 15-19 Female	
Т	est Result by Age and Sex:	
N	legative: 20-24 Female	
T	est Result by Age and Sex:	
N	legative: 25-49 Female	
Te	est Result by Age and Sex:	
N	legative: 50+ Female	
A	ggregated Age/sex - USE WITH	
H H	IQ PERMISSION ONLY: <15 Male	
	ggregated Age/sex - USE WITH	95
	IQ PERMISSION ONLY: 15+ Male	
	ggregated Age/sex - USE WITH	
	IQ PERMISSION ONLY: <15	
	emale	
	ggregated Age/sex - USE WITH	400
	IQ PERMISSION ONLY: 15+ emale	160
	est Result by Aggregated Age nd Sex: Negative <15 Male	
	est Result by Aggregated Age	
	nd Sex: Negative 15+ Male	
	est Result by Aggregated Age	
	nd Sex: Negative <15 Female	
	est Result by Aggregated Age	
	nd Sex: Negative 15+ Female	
	est Result by Aggregated Age	
	nd Sex: Positive <15 Male	
Т	est Result by Aggregated Age	10



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age	
	and Sex: Positive <15 Female	
	Test Result by Aggregated Age	0
	and Sex: Positive 15+ Female	8
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	
	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	055
	(Community): Mobile testing	255
	Service Delivery Point	
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
b	by Age: <15 other	
S	Service Delivery Point (Facility):	



Inpatient
Service Delivery Point (Facility):
Outpatient
Service Delivery Point (Facility):
Pediatric
Service Delivery Point (Facility):
Malnutrition facilities
Service Delivery Point (Facility):
Other PITC
Service Delivery Point (Facility):
VCT
Service Delivery Point (Facility):
VMMC
Service Delivery Point (Facility):
Service Delivery Point (Facility): TB
Service Delivery Point (Facility): Index testing
Service Delivery Point (Facility) by Age: <15 Inpatient
Service Delivery Point (Facility) by
Age: >15 Inpatient
Service Delivery Point (Facility) by
Age: <15 Outpatient
Service Delivery Point (Facility) by
Age: >15 Outpatient
Service Delivery Point (Facility) by
Age: <15 Pediatroc
Service Delivery Point (Facility) by
Age: >15 Pediatroc
Service Delivery Point (Facility) by
Age: <15 Malnutrition facilities
Service Delivery Point (Facility) by



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of individuals who received	
HTC_TST_TA	T&C services for HIV and received	527
	their test results during the past 12	
	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	234
HQ PERMISSION ONLY: 15+ Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	293
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	



and Sex: Positive <15 Male	
Test Result by Aggregated Age	14
and Sex: Positive 15+ Male	14
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	14
and Sex: Positive 15+ Female	14
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	



by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility): 95	
VCT 95	
Service Delivery Point (Facility):	
VMMC	
Service Delivery Point (Facility):	
PMTCT	
Service Delivery Point (Facility): TB	
Clinics	
Service Delivery Point (Facility):	
Index testing	
Service Delivery Point (Facility) by	
Age: <15 Inpatient	
Service Delivery Point (Facility) by	
Age: >15 Inpatient	
Service Delivery Point (Facility) by	
Age: <15 Outpatient	
Service Delivery Point (Facility) by	
Age: >15 Outpatient	
Service Delivery Point (Facility) by	
Age: <15 Pediatroc	
Service Delivery Point (Facility) by	
Age: >15 Pediatroc	



Age: <15 Malnutrition facilities Service Delivery Point (Facility) by Age: >15 Malnutrition facilities Service Delivery Point (Facility) by Age: <15 Other PITC Service Delivery Point (Facility) by Age: <15 Other PITC Service Delivery Point (Facility) by Age: <15 Other PITC Service Delivery Point (Facility) by Age: <15 VCT Service Delivery Point (Facility) by Age: <15 VMC Service Delivery Point (Facility) by Age: <15 VMMC Service Delivery Point (Facility) by Age: <15 VMMC Service Delivery Point (Facility) by Age: <15 VMMC Service Delivery Point (Facility) by Age: <15 PMTCT Service Delivery Point (Facility) by Age: <15 PMTCT Service Delivery Point (Facility) by Age: <15 TB Clinics Service Delivery Point (Facility) by Age: <15 TB Clinics Service Delivery Point (Facility) by Age: <15 TB Clinics Service Delivery Point (Facility) by Age: <15 Index testing Service Delivery Point (Facility) by Age: <15 Index testing		-	
Age: >15 Malnutrition facilities Service Delivery Point (Facility) by Age: <15 Other PITC		Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC		Service Delivery Point (Facility) by	
Age: <15 Other PITC		Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Other PITC Service Delivery Point (Facility) by Age: <15 VCT		Service Delivery Point (Facility) by	
Age: >15 Other PITC Service Delivery Point (Facility) by Age: <15 VCT		Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT		Service Delivery Point (Facility) by	
Age: <15 VCT		Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: >15 VCT Service Delivery Point (Facility) by Age: <15 VMMC		Service Delivery Point (Facility) by	
Age: >15 VCT Service Delivery Point (Facility) by Age: <15 VMMC		Age: <15 VCT	
Service Delivery Point (Facility) by Age: <15 VMMC		Service Delivery Point (Facility) by	
Age: <15 VMMC		Age: >15 VCT	
Service Delivery Point (Facility) by Age: >15 VMMC Service Delivery Point (Facility) by Age: <15 PMTCT		Service Delivery Point (Facility) by	
Age: >15 VMMC Service Delivery Point (Facility) by Age: <15 PMTCT		Age: <15 VMMC	
Service Delivery Point (Facility) by Age: <15 PMTCT		Service Delivery Point (Facility) by	
Age: <15 PMTCT		Age: >15 VMMC	
TX_CURR_TA Service Delivery Point (Facility) by Age: <15		Service Delivery Point (Facility) by	
Age: >15 PMTCT Service Delivery Point (Facility) by Age: <15 TB Clinics		Age: <15 PMTCT	
TX_CURR_TA Age/Sex: 5-14 Male Age/Sex: 5-14 Male Age/Sex: 5-14 Male		Service Delivery Point (Facility) by	
Age: <15 TB Clinics		Age: >15 PMTCT	
TX_CURR_TA Age/Sex: <1 Male		Service Delivery Point (Facility) by	
Age: >15 TB Clinics Service Delivery Point (Facility) by Age: <15 Index testing		Age: <15 TB Clinics	
Service Delivery Point (Facility) by Age: <15 Index testing		Service Delivery Point (Facility) by	
Age: <15 Index testing		Age: >15 TB Clinics	
Service Delivery Point (Facility) by Age: >15 Index testing Number of adults and children receiving antiretroviral therapy 464 (ART) TX_CURR_TA Age/Sex: <1 Male		Service Delivery Point (Facility) by	
Age: >15 Index testing Number of adults and children receiving antiretroviral therapy 464 (ART) TX_CURR_TA Age/Sex: <1 Male		Age: <15 Index testing	
Number of adults and children 464 receiving antiretroviral therapy 464 (ART) 464 TX_CURR_TA Age/Sex: <1 Male		Service Delivery Point (Facility) by	
receiving antiretroviral therapy 464 (ART) Age/Sex: <1 Male		Age: >15 Index testing	
TX_CURR_TA (ART) Age/Sex: <1 Male Age/Sex: 1-4 Male Age/Sex: 5-14 Male		Number of adults and children	
TX_CURR_TA Age/Sex: <1 Male			464
Age/Sex: 1-4 Male		(ART)	
Age/Sex: 5-14 Male	TX_CURR_TA	Age/Sex: <1 Male	
		Age/Sex: 1-4 Male	
Age/Sex: 15-19 Male		Age/Sex: 5-14 Male	
		Age/Sex: 15-19 Male	



Age/Sex: 20+ Male Age/Sex: <1 Female Age/Sex: 1-4 Female Age/Sex: 5-14 Female Age/Sex: 15-19 Female Age/Sex: 20+ Female	
Age/Sex: 1-4 Female Age/Sex: 5-14 Female Age/Sex: 15-19 Female	
Age/Sex: 5-14 Female Age/Sex: 15-19 Female	
Age/Sex: 15-19 Female	
Age/Sex: 20+ Female	
Sum of Age/Sex disaggregations	
Aggregated Age/Sex: <1 Male	
Aggregated Age/Sex: <1 Female	
Aggregated Age/Sex: <15 Male	
Aggregated Age/Sex: 1-14 Male	
Aggregated Age/Sex: 15+ Male 231	
Aggregated Age/Sex: <15 Female	
Aggregated Age/Sex: 1-14 Female	
Aggregated Age/Sex: 15+ Female 233	
Sum of Aggregated Age/Sex <15	
Sum of Aggregated Age/Sex 15+ 464	
Sum of Aggregated Age/Sex	
disaggregates 464	
Age/Sex: <1	
Age/Sex: 1-9	
Age/Sex: 10-14 Male	
Age/Sex: 10-14 Female	
Sum of Aggregated Age/Sex (<1	
and 1-14) <15	
Age/Sex: 20-24 Male	
Age/Sex: 25-49 Male	
Age/Sex: 50+ Male	
Age/Sex: 20-24 Female	
Age/Sex: 25-49 Female	
Age/Sex: 50+ Female	
TX_NEW_TA Number of adults and children 366	



newly enrolled on antiretroviral	
therapy (ART)	
By Age/Sex: <1	
By Age/Sex: 1-9	
By Age/Sex: <1 Male	
By Age/Sex: 1-4 Male	
By Age/Sex: 5-9 Male	
By Age/Sex: 10-14 Male	
By Age/Sex: 15-19 Male	
By Age/Sex: 20-24 Male	
By Age/Sex: 25-49 Male	
By Age/Sex: 50+ Male	
By Age/Sex: <1 Female	
By Age/Sex: 1-4 Female	
By Age/Sex: 5-9 Female	
By Age/Sex: 10-14 Female	
By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female	
By Age/Sex: 50+ Female	
Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <15 Male	
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	184
Aggregated Grouping by Age: <1 Female	
Aggregated Grouping by Age/Sex:	



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	182
	Sum of Aggregated Age/Sex disaggregates	366
	Pregnancy status	
	Breastfeeding status	
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral	n/a
	load (<1000 copies/ml)	
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	325
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	464
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	



Numerator: Age/Sex by Indication: 10-14 Female Routine
Numerator: Age/Sex by Indication: 10-14 Female Targeted
Numerator: Age/Sex by Indication: 10-14 Male Routine
Numerator: Age/Sex by Indication: 10-14 Male Targeted
Numerator: Age/Sex by Indication: 15-19 Female Routine
Numerator: Age/Sex by Indication: 15-19 Female Targeted
Numerator: Age/Sex by Indication: 15-19 Male Routine
Numerator: Age/Sex by Indication: 15-19 Male Targeted
Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Targeted
Numerator: Age/Sex by Indication: 20-24 Male Routine
Numerator: Age/Sex by Indication: 20-24 Male Targeted
Numerator: Age/Sex by Indication: 25-49 Female Routine
Numerator: Age/Sex by Indication: 25-49 Female Targeted
Numerator: Age/Sex by Indication: 25-49 Male Routine
Numerator: Age/Sex by Indication: 25-49 Male Targeted
Numerator: Age/Sex by Indication: 50+ Female Routine



Numerator: Age/Sex by Indication: 50+ Female Targeted
Numerator: Age/Sex by Indication: 50+ Male Routine
Numerator: Age/Sex by Indication: 50+ Male Targeted
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine
Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted
Numerator: Indication: Routine Numerator: Indication: Targeted
Numerator: Preg/BF by Indication: Breastfeeding Routine
Numerator: Preg/BF by Indication: Breastfeeding Targeted
Numerator: Preg/BF by Indication: Pregnant Routine
Numerator: Preg/BF by Indication: Pregnant Targeted
Denominator: Indication: Routine
Denominator: Indication: Targeted



Denominator: Age/Sex by Indication: <1 Routine Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by	۱	
Denominator: Age/Sex by Indication: <1 Targeted	Denominator: Age/Sex by	
Indication: <1 Targeted Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Indication: <1 Routine	
Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Hale Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Denominator: Age/Sex by	
Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Indication: <1 Targeted	
Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Indication: 1-9 Routine	
Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Helle Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Indication: 1-9 Targeted	
Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Indication: 10-14 Female Routine	
Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Male RoutineDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Indication: 10-14 Female Targeted	
Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Indication: 10-14 Male Routine	
Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Indication: 10-14 Male Targeted	
Denominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male Targeted	Indication: 15-19 Female Routine	
Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 15-19 Female Targeted	
Denominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 15-19 Male Routine	
Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 15-19 Male Targeted	
Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 20-24 Female Routine	
Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 20-24 Female Targeted	
Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 20-24 Male Routine	
Denominator: Age/Sex by	Denominator: Age/Sex by	
	Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by	
	Indication: 25-49 Female Routine	



Denominator: Age/Sex by
Indication: 25-49 Female Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Targeted
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Female Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Female Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Male Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Male Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Targeted
Denominator: Preg/BF by
Indication: Breastfeeding Routine
Denominator: Preg/BF by
Indication: Breastfeeding Targeted



	Denominator: Preg/BF by	
	Indication: Pregnant Routine	
	Denominator: Preg/BF by	
	Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex:	
	<15 Male	
	Numerator Aggregated Age/Sex:	162
	15+ Male	102
	Numerator Aggregated Age/Sex:	
	<15 Female	
	Numerator Aggregated Age/Sex:	100
	15+ Female	163
	Denominator Aggregated Age/Sex:	
	<15 Male	
	Denominator Aggregated Age/Sex:	
	15+ Male	231
	Denominator Aggregated Age/Sex:	
	<15 Female	
	Denominator Aggregated Age/Sex:	
	15+ Female	233
	Percentage of laboratories and	
	POC testing sites that perform HIV	
	diagnostic testing that participate	
	and successfully pass in an	
	analyte-specific proficiency testing	
	(PT) program	
	CD4: Number of laboratories that	
LAB_PT_TA	achieve acceptable successful	1
	passing criteria in this PT program	
	CD4: Number of laboratories that	
	participate in this PT program	1
	CD4: Number of laboratories that	
	perform this testing	1
	Early infant diagnostics: Number of	1
		•



laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
Early infant diagnostics: Number of	
laboratories that participate in this	1
PT program	
Early infant diagnostics: Number of	
laboratories that perform this	1
testing	
HIV serologic/diagnostic testing:	
Number of laboratories that	
achieve acceptable successful	8
passing criteria in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	8
participate in this PT program	-
HIV serologic/diagnostic testing:	
Number of laboratories that	8
perform this testing	-
HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	1
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	1
PT program	
HIV viral load: Number of	
laboratories that perform this	1
testing	·
TB diagnostics (AFB microscopy): Number of laboratories that	
achieve acceptable successful	3
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	3
Number of laboratories that	



	participate in this PT program	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	3
	perform this testing	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	achieve acceptable successful	0
	passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	achieve acceptable successful	0
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	perform this testing	
	Number of new HCW who	
	graduated from a pre-service	
	training institution or program as a	0
	result of PEPFAR-supported	2
	strengthening efforts, within the	
HRH_PRE	reporting period, by select cadre	
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service	
	workers	



	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,034
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	1,034
	Number of HIV ARVs purchased	
INVS_COMD	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	30,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Technical Area Summary Indicators and Targets

Trinidad and Tobago

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	1,000
	that are based on evidence and/or	1,000
	meet the minimum standards	
	required	
	Total estimated number of key	17,444
	population in the catchment area	17,444
KP_PREV_DSD	By key population type: Men who	
	have sex with men who are sex	
	workers (Numerator: Number of	
	key populations reached with	
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Men who	
	have sex with men who are NOT	
	sex workers (Numerator: Number	
	of key populations reached with	400
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	000
level HIV preventive interventions	600
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	6,616
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
` number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	10,828
Total estimated number of key	10,020
I Olai Estimateu number or key	



	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	<u> </u>
HTC_TST_TA	their test results during the past 12	600
	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Myersen. 20-43 Male	



Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	360
HQ PERMISSION ONLY: 15+ Male	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+	240
Female	240
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	



and Sex: Positive <15 Male	
Test Result by Aggregated Age	22
and Sex: Positive 15+ Male	22
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	10
and Sex: Positive 15+ Female	12
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	



by Age: <15 other
Service Delivery Point (Facility):
Inpatient
Service Delivery Point (Facility):
Outpatient
Service Delivery Point (Facility):
Pediatric
Service Delivery Point (Facility): Malnutrition facilities
Service Delivery Point (Facility): Other PITC
Service Delivery Point (Facility): VCT
Service Delivery Point (Facility): VMMC
Service Delivery Point (Facility): PMTCT
Service Delivery Point (Facility): TB Clinics
Service Delivery Point (Facility):
Index testing
Service Delivery Point (Facility) by
Age: <15 Inpatient
Service Delivery Point (Facility) by
Age: >15 Inpatient
Service Delivery Point (Facility) by
Age: <15 Outpatient
Service Delivery Point (Facility) by
Age: >15 Outpatient
Service Delivery Point (Facility) by Age: <15 Pediatroc
Service Delivery Point (Facility) by
Age: >15 Pediatroc
Service Delivery Point (Facility) by



	1	
	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of adults and children	
	receiving antiretroviral therapy	1,291
	(ART)	
TX_CURR_TA	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	



	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	645
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	646
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	1,291
	Sum of Aggregated Age/Sex	1 001
	disaggregates	1,291
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_TA	Number of adults and children	724



newly enrolled on antiretroviral	
therapy (ART)	
By Age/Sex: <1	
By Age/Sex: 1-9	
By Age/Sex: <1 Male	
By Age/Sex: 1-4 Male	
By Age/Sex: 5-9 Male	
By Age/Sex: 10-14 Male	
By Age/Sex: 15-19 Male	
By Age/Sex: 20-24 Male	
By Age/Sex: 25-49 Male	
By Age/Sex: 50+ Male	
By Age/Sex: <1 Female	
By Age/Sex: 1-4 Female	
By Age/Sex: 5-9 Female	
By Age/Sex: 10-14 Female	
By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female	
By Age/Sex: 50+ Female	
Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <15 Male	
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	374
Aggregated Grouping by Age: <1 Female	
Aggregated Grouping by Age/Sex:	



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	350
	Sum of Aggregated Age/Sex disaggregates	724
	Pregnancy status	
	Breastfeeding status	
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,162
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,291
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	



Numerator: Age/Sex by Indication: 10-14 Female Routine
Numerator: Age/Sex by Indication: 10-14 Female Targeted
Numerator: Age/Sex by Indication: 10-14 Male Routine
Numerator: Age/Sex by Indication: 10-14 Male Targeted
Numerator: Age/Sex by Indication: 15-19 Female Routine
Numerator: Age/Sex by Indication: 15-19 Female Targeted
Numerator: Age/Sex by Indication: 15-19 Male Routine
Numerator: Age/Sex by Indication: 15-19 Male Targeted
Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Targeted
Numerator: Age/Sex by Indication: 20-24 Male Routine
Numerator: Age/Sex by Indication: 20-24 Male Targeted
Numerator: Age/Sex by Indication: 25-49 Female Routine
Numerator: Age/Sex by Indication: 25-49 Female Targeted
Numerator: Age/Sex by Indication: 25-49 Male Routine
Numerator: Age/Sex by Indication: 25-49 Male Targeted
Numerator: Age/Sex by Indication: 50+ Female Routine



Numerator: Age/Sex by Indication: 50+ Female Targeted
Numerator: Age/Sex by Indication: 50+ Male Routine
Numerator: Age/Sex by Indication: 50+ Male Targeted
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine
Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted
Numerator: Indication: Routine Numerator: Indication: Targeted
Numerator: Preg/BF by Indication: Breastfeeding Routine
Numerator: Preg/BF by Indication: Breastfeeding Targeted
Numerator: Preg/BF by Indication: Pregnant Routine
Numerator: Preg/BF by Indication: Pregnant Targeted
Denominator: Indication: Routine
 Denominator: Indication: Targeted



Denominator: Age/Sex by Indication: <1 Routine Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by	۱	
Denominator: Age/Sex by Indication: <1 Targeted	Denominator: Age/Sex by	
Indication: <1 Targeted Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Indication: <1 Routine	
Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Hale Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Denominator: Age/Sex by	
Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Indication: <1 Targeted	
Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Indication: 1-9 Routine	
Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Helle Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Indication: 1-9 Targeted	
Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Indication: 10-14 Female Routine	
Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Male RoutineDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Indication: 10-14 Female Targeted	
Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Indication: 10-14 Male Routine	
Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Indication: 10-14 Male Targeted	
Denominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male Targeted	Indication: 15-19 Female Routine	
Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 15-19 Female Targeted	
Denominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 15-19 Male Routine	
Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 15-19 Male Targeted	
Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 20-24 Female Routine	
Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 20-24 Female Targeted	
Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by	Denominator: Age/Sex by	
Indication: 20-24 Male Targeted Denominator: Age/Sex by	Indication: 20-24 Male Routine	
Denominator: Age/Sex by	Denominator: Age/Sex by	
	Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by	
	Indication: 25-49 Female Routine	



Denominator: Age/Sex by
Indication: 25-49 Female Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Targeted
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Female Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Female Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Male Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Male Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Targeted
Denominator: Preg/BF by
Indication: Breastfeeding Routine
Denominator: Preg/BF by
Indication: Breastfeeding Targeted



passing criteria in this PT program CD4: Number of laboratories that 4 4 4 4			
LAB_PT_TA Denominator: Preg/BF by Indication: Pregnant Targeted Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregater Age/Sex: <1646 Denominator Aggregater Age/			
Indication: Pregnant Targeted Numerator Aggregated Age/Sex: <15 Male		Indication: Pregnant Routine	
Numerator Aggregated Age/Sex: <15 Male			
15+ Male 581 Numerator Aggregated Age/Sex: <15 Female		Numerator Aggregated Age/Sex:	
<15 Female			581
15+ Female 581 Denominator Aggregated Age/Sex: <15 Male			
<15 Male			581
15+ Male 645 Denominator Aggregated Age/Sex: <15 Female			
<15 Female			645
15+ Female 646 Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program LAB_PT_TA CD4: Number of laboratories that achieve acceptable successful 4 passing criteria in this PT program CD4: Number of laboratories that			
POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program (PT) program CD4: Number of laboratories that 4 passing criteria in this PT program CD4: Number of laboratories that CD4: Number of laboratories that 4			646
LAB_PT_TA achieve acceptable successful 4 passing criteria in this PT program 2 CD4: Number of laboratories that 4		POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing	
4	LAB_PT_TA	achieve acceptable successful	4
participate in this PT program		CD4: Number of laboratories that participate in this PT program	4
CD4: Number of laboratories that 4			4
Early infant diagnostics: Number of 1		Early infant diagnostics: Number of	1



laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
Early infant diagnostics: Number of	
laboratories that participate in this	1
PT program	
Early infant diagnostics: Number of	
laboratories that perform this	1
testing	
HIV serologic/diagnostic testing:	
Number of laboratories that	
achieve acceptable successful	9
passing criteria in this PT program	
HIV serologic/diagnostic testing:	0
Number of laboratories that	9
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	9
perform this testing	
HIV viral load: Number of	
laboratories that achieve	1
acceptable successful passing	·
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	1
PT program	
HIV viral load: Number of	
laboratories that perform this	1
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	6
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
	6
 Number of laboratories that	



	participate in this PT program	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	6
	perform this testing	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	achieve acceptable successful	0
	passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	0
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	achieve acceptable successful	0
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	0
	perform this testing	
	Number of new HCW who	
	graduated from a pre-service	
HRH_PRE	training institution or program as a	4
	result of PEPFAR-supported	4
	strengthening efforts, within the	
	reporting period, by select cadre	
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service	
	workers	



	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,764
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
INVS_COMD	Number of HIV Viral Load Reagents purchased	1,764
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	30,000
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	60,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Technical Area Summary Indicators and Targets

Caribbean Region

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	0.404
	that are based on evidence and/or	8,184
	meet the minimum standards	
	required	
	Total estimated number of key	07.4.40
	population in the catchment area	67,142
KP_PREV_DSD	By key population type: Men who	
	have sex with men who are sex	
	workers (Numerator: Number of	
	key populations reached with	
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Men who	
	have sex with men who are NOT	
	sex workers (Numerator: Number	
	of key populations reached with	3,921
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	1 000
level HIV preventive interventions	4,263
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	35,496
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
` number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	31,646
Total estimated number of key	51,040
I GIAI ESUINALEU NUMBEI OI KEY	



		I
	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	KP_PREV_TA Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
KP_PREV_TA	based on evidence and/or meet the	
	minimum standards required	
	(TA-only)	
	Number of key populations reached	
	with individual and/or small group	118



level HIV preventive interventions that are based on evidence and/or meet the minimum standards required Total estimated number of key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominato		
meet the minimum standards required376Total estimated number of key population in the catchment area376By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population sreached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population inpe: Males who	level HIV preventive interventions	
required 376 Total estimated number of key 376 population in the catchment area 376 By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population	that are based on evidence and/or	
Total estimated number of key 376 population in the catchment area 376 By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: </td <td>meet the minimum standards</td> <td></td>	meet the minimum standards	
population in the catchment area 376 By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female <td< td=""><td>required</td><td></td></td<>	required	
population in the catchment area By key population type: Sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evide	Total estimated number of key	
sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who	population in the catchment area	376
sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who	By key population type: Female	
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female OWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in t		
that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex do ne vidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who	• ·	
meet the minimum standards required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population type: Males who		
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who	, ·	
preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population type: Males who		
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type:Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population type:Males who		
who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who	,	
and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who	• .	
minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who		
Total estimated number of key population in the catchment area)By key population type: Males who		
population in the catchment area) By key population type: Males who		
By key population type: Males who	-	
	population in the catchment area)	
inject drugs (Male PWID)	By key population type: Males who	
	 inject drugs (Male PWID)	



í		
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Men who	
	have sex with men and are sex	
	workers (Numerator: Number of	
	key populations reached with	
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Men who	
	have sex with men and are NOT	
	sex workers (Numerator: Number	
	of key populations reached with	
	individual and/or small group level	118
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type:	
	Transgender who are sex workers	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type:	
	Transgender who are NOT sex	
	workers (Numerator: Number of	
	key populations reached with	



i	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Men who	
	have sex with men and are sex	
	workers (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By key population type: Men who	
	have sex with men and are NOT	
	sex workers (Denominator: Total	376
	estimated number of key	
	population in the catchment area)	
	By key population type:	
	Transgender who are sex workers	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type:	
	Transgender who are NOT sex	
,	workers (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
		· · · · · · · · · · · · · · · · · · ·



	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received T&C services for HIV and received	
	their test results during the past 12	6,721
	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
HTC_TST_DSD	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex:	
	Positive: 10-14 Male	
	Test Result by Age and Sex:	
	Positive: 15-19 Male	
	Test Result by Age and Sex:	
	Positive: 20-24 Male	



Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male
Test Result by Age and Sex:
Negative: 10-14 Female
Test Result by Age and Sex:
Negative: 15-19 Female
Test Result by Age and Sex:
Negative: 20-24 Female
Test Result by Age and Sex:
Negative: 25-49 Female
Test Result by Age and Sex:
Negative: 50+ Female



Aggregated Age/sex - USE WITH 83 Aggregated Age/sex - USE WITH 3,238 Aggregated Age/sex - USE WITH 3,238 Aggregated Age/sex - USE WITH 3,238 Aggregated Age/sex - USE WITH 13,238 Aggregated Age/sex - USE WITH 73 Female 73 Female 3,327 Test Result by Aggregated Age 3,327 Female Test Result by Aggregated Age and Sex: Negative 15 + Male 1 Test Result by Aggregated Age 6 and Sex: Nogative 15 + Female 229 and Sex: Positive 15 + Male 229 and Sex: Positive 15 + Female 131 Test Result by Aggregated Age 4 <		
HQ PERMISSION ONLY: 15+ Male3,238Aggregated Age/sex - USE WITHHQ PERMISSION ONLY: <15		83
HQ PERMISSION ONLY: <1573FemaleAggregated Age/sex - USE WITHHQ PERMISSION ONLY: 15+3,327FemaleTest Result by Aggregated Ageand Sex: Negative <15 Male		3,238
HQ PERMISSION ONLY: 15+ Female3,327FemaleTest Result by Aggregated Age and Sex: Negative <15 Male	HQ PERMISSION ONLY: <15	73
and Sex: Negative <15 Male	HQ PERMISSION ONLY: 15+	3,327
and Sex: Negative 15+ MaleTest Result by Aggregated Ageand Sex: Negative <15 Female		
and Sex: Negative <15 Female	,	
and Sex: Negative 15+ FemaleTest Result by Aggregated Age and Sex: Positive <15 Male		
and Sex: Positive <15 Male6Test Result by Aggregated Age and Sex: Positive 15+ Male229Test Result by Aggregated Age and Sex: Positive <15 Female	,	
and Sex: Positive 15+ Male229Test Result by Aggregated Age and Sex: Positive <15 Female	,	6
and Sex: Positive <15 Female		229
and Sex: Positive 15+ Female131Test Result by Age: Positive: <1		4
Test Result by Age: Positive: 1-9 Age/sex: <1		131
Age/sex: <1	Test Result by Age: Positive: <1	
Age/sex: 1-9 Service Delivery Point (Community): Index testing Service Delivery Point	Test Result by Age: Positive: 1-9	
Service Delivery Point (Community): Index testing Service Delivery Point	Age/sex: <1	
(Community): Index testing 150 Service Delivery Point	Age/sex: 1-9	
	-	150
	Service Delivery Point (Community): Homebased testing	



Service Delivery Point	
(Community): Mobile testing	1,994
Service Delivery Point	
(Community): Other	2,562
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	1,655
Other PITC	.,
Service Delivery Point (Facility):	
VCT	
Service Delivery Point (Facility):	
VMMC	



Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	300
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by Age: <15 VMMC	
Service Delivery Point (Facility) by Age: >15 VMMC	



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics Service Delivery Point (Facility) by	
	Age: <15 Index testing Service Delivery Point (Facility) by	
	Age: >15 Index testing Number of individuals who received T&C services for HIV and received their test results during the past 12	2,103
	months Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
HTC_TST_TA	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex:	
	Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex:	
	•	



Positive: 20-24 MaleTest Result by Age and Sex:Positive: 25-49 MaleTest Result by Age and Sex:Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 50+ Male
Positive: 25-49 MaleTest Result by Age and Sex:Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex: Negative: 10-14 MaleTest Result by Age and Sex: Negative: 15-19 MaleTest Result by Age and Sex: Negative: 20-24 MaleTest Result by Age and Sex: Negative: 25-49 MaleTest Result by Age and Sex: Negative: 25-49 MaleTest Result by Age and Sex: Negative: 25-49 Male
Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Test Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex:
Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex:
Negative: 25-49 Male Test Result by Age and Sex:
Test Result by Age and Sex:
Negative: 50+ Male
Test Result by Age and Sex:
Negative: <1 Female
Test Result by Age and Sex:
Negative: 10-14 Female
Test Result by Age and Sex:
Negative: 15-19 Female
Test Result by Age and Sex:
Negative: 20-24 Female



	Negative: 25-49 Female	
	Test Result by Age and Sex:	
1	Negative: 50+ Female	
	Aggregated Age/sex - USE WITH	
ŀ	HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH	982
ŀ	HQ PERMISSION ONLY: 15+ Male	302
	Aggregated Age/sex - USE WITH	
	HQ PERMISSION ONLY: <15	
	Female	
I	Aggregated Age/sex - USE WITH	
	HQ PERMISSION ONLY: 15+	1,121
1	Female	
	Test Result by Aggregated Age	
	and Sex: Negative <15 Male	
	Test Result by Aggregated Age	
i	and Sex: Negative 15+ Male	
	Test Result by Aggregated Age	
2	and Sex: Negative <15 Female	
	Test Result by Aggregated Age	
ć	and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	
	and Sex: Positive <15 Male	
I	Test Result by Aggregated Age	68
	and Sex: Positive 15+ Male	~~
	Test Result by Aggregated Age	
	and Sex: Positive <15 Female	
	Test Result by Aggregated Age	56
	and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
ł	Age/sex: <1	
Α	Age/sex: 1-9	
Se	ervice Delivery Point	
4		



(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	4.4
(Community): Other	14
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	95



VCT
Service Delivery Point (Facility):
VMMC
Service Delivery Point (Facility):
РМТСТ
Service Delivery Point (Facility): TB
Clinics
Service Delivery Point (Facility):
Index testing
Service Delivery Point (Facility) by
Age: <15 Inpatient
Service Delivery Point (Facility) by
Age: >15 Inpatient
Service Delivery Point (Facility) by
Age: <15 Outpatient
Service Delivery Point (Facility) by
Age: >15 Outpatient
Service Delivery Point (Facility) by
Age: <15 Pediatroc
Service Delivery Point (Facility) by
Age: >15 Pediatroc
Service Delivery Point (Facility) by
Age: <15 Malnutrition facilities
Service Delivery Point (Facility) by
Age: >15 Malnutrition facilities
Service Delivery Point (Facility) by
Age: <15 Other PITC
Service Delivery Point (Facility) by
Age: >15 Other PITC
Service Delivery Point (Facility) by
Age: <15 VCT
Service Delivery Point (Facility) by
Age: >15 VCT
Service Delivery Point (Facility) by



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	162
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
OVC_SERV_DSD	Age/Sex: 18+ Male	52
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	83
	Sum of Age/Sex disaggregates	135
	Required only for DREAMS	
	countries - By service, age and	
	sex: Education Support Female <1	



Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female	
25+	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male <1	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male 10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Male 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Female <1	



Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	
Female 15-17 Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



Male 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Female <1	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Female	
10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Female	
15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Female	
18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male <1	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male 10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male 25+	
Required only for DREAMS	



countries - By service, age and	
sex: Economic Strengthening	
Female <1	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
<1	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
18-24	



r	1
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
25+	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Female <1	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Female 10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Female 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Female 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male <1	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 10-14	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 25+	
 Age/Sex: <1	



	[]
Age/Sex: 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support 1-9 Male	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Male 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Programs	
Male 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 1-9	
Program Completion: Active	
Program Completion: Graduation	
Program Completion: Transferred	
Program Completion: Exited	
without graduation	
By Aggregated Age/Sex: <18 Male	12
By Aggregated Age/Sex: 18+ Male	
By Aggregated Age/Sex: <18	
Female	15
By Aggregated Age/Sex: 18+	
Female	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female 1-9	
Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs	
	Female 1-9 Required only for DREAMS countries - By service, age and sex: Social Protection Programs	
	Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,718
	Screened for TB by Age/Sex:<15 Male	9
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	644
	Screened for TB by Age/Sex:<15 Female	35
	Screened for TB by Age/Sex: 15+ Female	1,030
	Screen Result: Screened Positive for TB	35
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	



	[Sub-Disagg of Screen Result]	
	Specimen Sent: Specimen sent for	35
	bacteriologic diagnosis of active TB	
	[Sub-Disagg of Specimen Sent]	07
	Diagnostic Test: Smear only	27
	[Sub-Disagg of Specimen Sent]	
	Diagnostic Test: Xpert MTB/RIF	8
	assay	
	[Sub-Disagg of Specimen Sent]	
	Diagnostic Test: other (not Xpert)	
	The number of PLHIV who were	
	screened for TB symptoms at the	
	last clinical visit at a HIV facility	1,861
	during the reporting period.	
	Screened for TB by Age/Sex: <15	
	Male	100
	Screened for TB by Age/Sex: 15+	
	Male	837
	Screened for TB by Age/Sex: <15	
	Female	94
	Screened for TB by Age/Sex: 15+	
	Female	830
TB_SCREENDX_TA	Screen Results: Screened Positive	
	for TB	38
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15	
	Female	
	TB Positive by Age/Sex: 15+	
	Female	
	[Sub-Disagg of Screen Results]	
	Specimen Sent: Specimen sent for	38
	bacteriologic diagnosis of active TB	
	[Sub-disagg of Specimen Sent]	29
	[Oub disagg of Opecimen Cent]	25



	Diagnostic Test: Smear Only	
	[Sub-disagg of Specimen Sent]	
	Diagnostic Test: Xpert MTB/RIF	9
	assay	
	[Sub-disagg of Specimen Sent]	
	Diagnostic Test: Other (Not Xpert)	
	PMTCT_EID_TA Percent of infants	
	born to HIV-positive women that	
	receive a virological HIV test within	n/a
	12 months of birth (TA)	
	Number of infants who had a	
	virologic HIV test within 12 months	
	of birth during the reporting period	
	Number of HIV- positive pregnant	
	women identified during the	
	reporting period (include known	
	HIV-positive women at entry into	
	PMTCT)	
	By infants who received a virologic	
	test within 2 months of birth	38
PMTCT_EID_TA	By infants who received their first	
	virologic HIV test between 2 and 12	2
	months of age	
	Sum of Infant Age disaggregates	40
	By infants with a positive virologic	
	test result within 12 months of birth	
	Number of infants with a positive	
	virological test result within 2	0
	months of birth	
	Number of infants with a negative	
	virological test result within 2	
	months of birth	
	Number of infants with a positive	
	virological test result between 2	
	and 12 months of birth	



	Number of infants with a negative	
	virological test result between 2	
	and 12 months of birth	
	Number of infants with a positive	
	virological test result within 12	0
	months of birth	
	Number of adults and children	
	receiving antiretroviral therapy	1,718
	(ART)	
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	9
	Aggregated Age/Sex: 15+ Male	644
	Aggregated Age/Sex: <15 Female	35
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,030
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	44
	Sum of Aggregated Age/Sex 15+	1,674
	Sum of Aggregated Age/Sex	
	disaggregates	1,718
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	



	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children	
	receiving antiretroviral therapy	17,922
	(ART)	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
TX_CURR_TA	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	94
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	8,714
	Aggregated Age/Sex: <15 Female	100
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	9,015
	Sum of Aggregated Age/Sex <15	194
	Sum of Aggregated Age/Sex 15+	17,729
	Sum of Aggregated Age/Sex	17,923
	disaggregates	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	



	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	_
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,706
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
TX_NEW_DSD	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <a><15 Male	2
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex:	814



	15+ Male	
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2
	Aggregated Grouping by Age/Sex: 15+ Female	888
	Sum of Aggregated Age/Sex disaggregates	1,706
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,902
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
TX_NEW_TA	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	



	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	82
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,869
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <pre><15 Female</pre>	28
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,929
	Sum of Aggregated Age/Sex disaggregates	3,908
	Pregnancy status	
	Breastfeeding status	
	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information	n/a
	systems (LIS) within the past 12	n/a
TX_PVLS_DSD	months with a suppressed viral	
	load (<1000 copies/ml)	
	Number of adults and pediatric	
	patients on ART with suppressed	4.400
	viral load results (<1,000 copies/ml)	1,160
	documented in the medical records	



and /or supporting laboratory	
results within the past 12 months.	
Number of adult and pediatric ART patients with a viral load result	1,546
documented in the patient medical record and /or laboratory records in the past 12 months.	1,040
Numerator: Indication: Routine	1,160
Numerator: Indication: Targeted	
Numerator: Preg/BF by Indication: Pregnant Routine	
Numerator: Preg/BF by Indication: Breastfeeding Routine	
Numerator: Preg/BF by Indication: Pregnant Targeted	
Numerator: Preg/BF by Indication: Breastfeeding Targeted	
Numerator: Age/Sex by Indication: <1 Routine	
Numerator: Age/Sex by Indication: 1-9 Routine	
Numerator: Age/Sex by Indication: 10-14 Male Routine	
Numerator: Age/Sex by Indication: 15-19 Male Routine	
Numerator: Age/Sex by Indication: 20-24 Male Routine	
Numerator: Age/Sex by Indication: 25-49 Male Routine	
Numerator: Age/Sex by Indication: 50+ Male Routine	
Numerator: Age/Sex by Indication: 10-14 Female Routine	



15-19 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 25-49 Female Routine
Numerator: Age/Sex by Indication:
50+ Female Routine
Numerator: Age/Sex by Indication:
<1 Targeted
Numerator: Age/Sex by Indication:
1-9 Targeted
Numerator: Age/Sex by Indication:
10-14 Male Targeted
Numerator: Age/Sex by Indication:
15-19 Male Targeted
Numerator: Age/Sex by Indication:
20-24 Male Targeted
Numerator: Age/Sex by Indication:
25-49 Male Targeted
Numerator: Age/Sex by Indication:
50+ Male Targeted
Numerator: Age/Sex by Indication:
10-14 Female Targeted
Numerator: Age/Sex by Indication:
15-19 Female Targeted
Numerator: Age/Sex by Indication:
20-24 Female Targeted
Numerator: Age/Sex by Indication:
25-49 Female Targeted
Numerator: Age/Sex by Indication:
50+ Female Targeted
Numerator: Aggregate Age/Sex by
Indication: <15 Male Targeted
Numerator: Aggregate Age/Sex by



	Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by	
	Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by	
	Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by	
	Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by	
	Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by	
	Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by	
	Indication: 15+ Female Routine	
	Denominator: Indication: Routine	1,546
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by	
ļ	Indication: Pregnant Routine	
	Denominator: Preg/BF by	
ļ	Indication: Breastfeeding Routine	
	Denominator: Preg/BF by	
	Indication: Pregnant Targeted	
	Denominator: Preg/BF by	
	Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by	
	Indication: <1 Routine	
	Denominator: Age/Sex by	
	Indication: 1-9 Routine	
	Denominator: Age/Sex by	
	Indication: 10-14 Male Routine	
	Denominator: Age/Sex by	
ļ	Indication: 15-19 Male Routine	
	Denominator: Age/Sex by	
	Indication: 20-24 Male Routine	
_	Denominator: Age/Sex by	



Indication: 25-4	49 Male Routine
Denominator: /	Age/Sex by
Indication: 50+	- Male Routine
Denominator: /	Age/Sex by
Indication: 10-7	14 Female Routine
Denominator: /	Age/Sex by
Indication: 15-7	19 Female Routine
Denominator: <i>i</i>	Age/Sex by
Indication: 20-2	24 Female Routine
Denominator: <i>i</i>	Age/Sex by
Indication: 25-4	49 Female Routine
Denominator: <i>i</i>	Age/Sex by
Indication: 50+	- Female Routine
Denominator: <i>i</i>	Age/Sex by
Indication: <1	Targeted
Denominator: /	Age/Sex by
Indication: 1-9	Targeted
Denominator: /	Age/Sex by
Indication: 10-	14 Male Targeted
Denominator: /	Age/Sex by
Indication: 15-	19 Male Targeted
Denominator: /	Age/Sex by
Indication: 20-2	24 Male Targeted
Denominator: A	Age/Sex by
Indication: 25-4	49 Male Targeted
Denominator: A	Age/Sex by
Indication: 50+	- Male Targeted
Denominator: A	Age/Sex by
Indication: 10-	14 Female Targeted
Denominator: A	Age/Sex by
Indication: 15-	19 Female Targeted
Denominator: A	Age/Sex by
Indication: 20-2	24 Female Targeted
Denominator: <i>i</i>	Ago/Cox by



	Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by	
	Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex	
	by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex	
ļ	by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex	
	by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex	
	by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex	
	by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex	
1	by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex:	29
	<15 Male	23
	Numerator Aggregated Age/Sex:	543
	15+ Male	070
	Numerator Aggregated Age/Sex:	29
	<15 Female	23
	Numerator Aggregated Age/Sex:	559
ļ	15+ Female	
	Denominator Aggregated Age/Sex:	38
	<15 Male	
	Denominator Aggregated Age/Sex:	715
ŀ	15+ Male	
	Denominator Aggregated Age/Sex:	40
<	15 Female	
De	enominator Aggregated Age/Sex:	753



	15+ Female	
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	14,186
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,736
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	



Numerator: Age/Sex by Indication: 15-19 Female Routine
Numerator: Age/Sex by Indication: 15-19 Female Targeted
Numerator: Age/Sex by Indication: 15-19 Male Routine
Numerator: Age/Sex by Indication: 15-19 Male Targeted
Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Targeted
Numerator: Age/Sex by Indication: 20-24 Male Routine
Numerator: Age/Sex by Indication: 20-24 Male Targeted
Numerator: Age/Sex by Indication: 25-49 Female Routine
Numerator: Age/Sex by Indication: 25-49 Female Targeted
Numerator: Age/Sex by Indication: 25-49 Male Routine
Numerator: Age/Sex by Indication: 25-49 Male Targeted
Numerator: Age/Sex by Indication: 50+ Female Routine
Numerator: Age/Sex by Indication: 50+ Female Targeted
Numerator: Age/Sex by Indication: 50+ Male Routine
Numerator: Age/Sex by Indication: 50+ Male Targeted
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine



L	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Indication: Routine	1,256
Numerator: Indication: Targeted	
Numerator: Preg/BF by Indication:	
Breastfeeding Routine	
Numerator: Preg/BF by Indication:	
Breastfeeding Targeted	
Numerator: Preg/BF by Indication:	
Pregnant Routine	
Numerator: Preg/BF by Indication:	
Pregnant Targeted	
Denominator: Indication: Routine	1,675
Denominator: Indication: Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: <1 Targeted	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
Denominator: Age/Sex by	
Indication: 1-9 Targeted	



Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 10-14 Female Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Female Routine



Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Male Routine	
Denominator: Age/Sex by	
Indication: 50+ Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Targeted	
Denominator: Preg/BF by	
Indication: Breastfeeding Routine	
Denominator: Preg/BF by	
Indication: Breastfeeding Targeted	
Denominator: Preg/BF by	
Indication: Pregnant Routine	
Denominator: Preg/BF by	
Indication: Pregnant Targeted	
Numerator Aggregated Age/Sex:	F (
<15 Male	51
Numerator Aggregated Age/Sex:	0.007
15+ Male	6,897



	Numerator Aggregated Age/Sex: <15 Female	73
	Numerator Aggregated Age/Sex: 15+ Female	7,165
	Denominator Aggregated Age/Sex: <15 Male	77
	Denominator Aggregated Age/Sex: 15+ Male	8,629
	Denominator Aggregated Age/Sex: <15 Female	91
	Denominator Aggregated Age/Sex: 15+ Female	8,939
	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	151
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	178
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 10-14 Male (Numerator:	



Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sed: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 25-49 Female	



(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: s1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those died those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those period, period, including those period, period, including those prior to the beginning of the reporting period, including those period, period, including those prior to the beginning of the reporting period, including the reporting period, including those period, period, including those peri	(Numerator: Number of adults and	
initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART, in the 12 months prior to the beginning of the reporting period, including those who have died, ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of <	children who are still alive and on	
Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, <t< td=""><td>treatment at 12 months after</td><td></td></t<>	treatment at 12 months after	
Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up)	initiating ART	
are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up)	Age/Sex: 50+ Female (Numerator:	
12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up)	Number of adults and children who	
Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	are still alive and on treatment at	
number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART, and those lost to follow-up)	12 months after initiating ART	
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	Age/Sex: >1 (Denominator: Total	
to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have follow-up)	number of adults and children who	
period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	initiated ART in the 12 months prior	
died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	to the beginning of the reporting	
ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	period, including those who have	
Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated	died, those who have stopped	
number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	ART, and those lost to follow-up)	
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	Age/Sex: 1-9 (Denominator: Total	
to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	number of adults and children who	
period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	initiated ART in the 12 months prior	
died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	to the beginning of the reporting	
ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	period, including those who have	
Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	died, those who have stopped	
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	ART, and those lost to follow-up)	
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	Age/Sex: 10-14 Male	
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	(Denominator: Total number of	
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	adults and children who initiated	
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	ART in the 12 months prior to the	
those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	beginning of the reporting period,	
those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	including those who have died,	
Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	those who have stopped ART, and	
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	those lost to follow-up)	
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	Age/Sex: 15-19 Male	
ART in the 12 months prior to the beginning of the reporting period,	(Denominator: Total number of	
beginning of the reporting period,	adults and children who initiated	
	ART in the 12 months prior to the	
including those who have died,	beginning of the reporting period,	
	including those who have died,	



those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Male (Denominator:
Age/Sex: 50+ Male (Denominator: Total number of adults and children
-
Total number of adults and children
Total number of adults and children who initiated ART in the 12 months
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and



adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Aggregated Age: <15 (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Aggregated Age: 15+ (Numerator:
Number of adults and children who



are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	
Numerator by Status:	
Breastfeeding	
Denominator by Status: Pregnant	
Denominator by Status:	
Breastfeeding	
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	
children who are still alive and on	7
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Male	
(Numerator: Number of adults and	
children who are still alive and on	64
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Female	8



(Numerator: Number of adults and children who are still alive and on treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and	
children who are still alive and on	72
treatment at 12 months after	12
initiating ART)	
Aggregated Age/Sex: <15 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	8
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	70
beginning of the reporting period,	76
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: <15 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	10
beginning of the reporting period,	10
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Female	
(Denominator: Total number of	84
adults and children who initiated	
	L



<u> </u>		
٩	ART in the 12 months prior to the	
d	beginning of the reporting period,	
ir	ncluding those who have died,	
ti	hose who have stopped ART, and	
ti	hose lost to follow-up)	
Т	TX_RET_TA Percent of adults and	
c	children known to be alive and on	- (-
tı	reatment 12 months after initiation	n/a
0	of antiretroviral therapy	
	Number of adults and children who	
a	are still alive and on treatment at	200
1	12 months after initiating ART	
Т	Fotal number of adults and children	
w	who initiated ART in the 12 months	
p	prior to the beginning of the	
r.	eporting period, including those	227
w	who have died, those who have	
s	stopped ART, and those lost to	
fo	ollow-up	
	Age/Sex: <1 (Numerator: Number	
TX_RET_TA	of adults and children who are still	
a	alive and on treatment at 12	
n	months after initiating ART)	
4	Age/Sex: 1-9 (Numerator: Number	
0	of adults and children who are still	
a	alive and on treatment at 12	
n n	months after initiating ART)	
A	Age/Sex: 10-14 Male (Numerator:	
	Number of adults and children who	
a	are still alive and on treatment at	
1	12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator:	
	Number of adults and children who	
	are still alive and on treatment at	
la		



Age/Sex: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 50+ Female (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
5 /	



Age/Sex: <1 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 1-9 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	



those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Male (Denominator:
Total number of adults and children
who initiated ART in the 12 months
prior to the beginning of the
reporting period, including those
who have died, those who have
stopped ART, and those lost to
follow-up)
Age/Sex: 10-14 Female
Age/Sex: 10-14 Female (Denominator: Total number of
_
(Denominator: Total number of
(Denominator: Total number of adults and children who initiated
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and



adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
	_
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	



	1
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	
Numerator by Status:	
Breastfeeding	
Denominator by Status: Pregnant	
Denominator by Status:	
Breastfeeding	
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	
children who are still alive and on	10
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Male	
(Numerator: Number of adults and	
children who are still alive and on	86
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Female	
(Numerator: Number of adults and	
children who are still alive and on	10
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Female	
(Numerator: Number of adults and	
` children who are still alive and on	94
treatment at 12 months after	
	1



	initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	95
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate	



a	and successfully pass in an	
a	analyte-specific proficiency testing	
<u>(</u> F	PT) program	
c	CD4: Number of laboratories that	
a	achieve acceptable successful	11
р	passing criteria in this PT program	
c	CD4: Number of laboratories that	
p	participate in this PT program	11
C	CD4: Number of laboratories that	
р	perform this testing	11
E	Early infant diagnostics: Number of	
la	aboratories that achieve	_
a	acceptable successful passing	5
С	riteria in this PT program	
E	Early infant diagnostics: Number of	
la	aboratories that participate in this	5
Р	PT program	
E	Early infant diagnostics: Number of	
la	aboratories that perform this	5
te	esting	
н	HV serologic/diagnostic testing:	
N	Number of laboratories that	
a	achieve acceptable successful	44
p	passing criteria in this PT program	
н	HV serologic/diagnostic testing:	
	Number of laboratories that	44
p	participate in this PT program	
н	HV serologic/diagnostic testing:	
	Number of laboratories that	44
	perform this testing	
	HV viral load: Number of	
	aboratories that achieve	
	acceptable successful passing	5
	riteria in this PT program	
	HV viral load: Number of	5
		5



	1
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	5
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	17
achieve acceptable successful	17
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	17
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	17
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	0
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	0
participate in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	0
perform this testing	
TB diagnostics (Culture/DST):	
Number of laboratories that	
achieve acceptable successful	0
passing criteria in this PT program	
TB diagnostics (Culture/DST):	
Number of laboratories that	0
participate in this PT program	
TB diagnostics (Culture/DST):	
Number of laboratories that	0
perform this testing	



	Number of new HCW who	
	graduated from a pre-service	
	training institution or program as a	40
	result of PEPFAR-supported	12
	strengthening efforts, within the	
	reporting period, by select cadre	
	By Graduates: Doctors	
HRH_PRE	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service	
	workers	
	By Graduates: Laboratory	
	professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
	PEPFAR resources used for	
	HIV-program related commodities:	10,930
	planned & purchased in the last 12	10,330
	months by Implementing Partner	
	Number of HIV Test Kits purchased	1,889
	Number of HIV CD4 Reagents	
	purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load	7 609
INVS_COMD	Reagents purchased	7,698
	Number of HIV ARVs purchased	1,343
	Number of Second Line HIV ARVs	
	purchased	
	HIV Test Kits: Dollars planned	10.400
	(COP)/ spent (Actual)	10,198
	HIV CD4 Tests: Dollars planned	80,000
	(COP)/ spent (Actual)	00,000
	HIV Viral Load: Dollars planned	285 590
	(COP)/ spent (Actual)	285,580



Condoms: Dollars planned (COP)/ spent (Actual)	
HIV ARVs: Dollars planned (COP)/ spent (Actual)	161,160



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12542	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
12567	Jamaica Ministry of Health (MOH)	Host Country Government Agency	U.S. Agency for International Development	GHP-State	3,105,000
12570	Bahamas MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12575	Pan American Health Organization (PAHO)/PAHO HIV Caribbean Office (PHCO)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
12587	US Embassies	Other USG Agency	U.S. Department of State/Bureau of Western Hemisphere	GHP-State	200,000



			Affairs		
12588	Caribbean Community (CARICOM) Pan Caribbean Partnership Against AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-USAID	200,000
12594	HRM	Other USG Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12606	Barbados MOH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12642	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12645	World Learning	NGO	U.S. Agency for International Development	GHP-USAID	0
12668	Trinidad MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Caribbean		Human		
12688	Regional Public	Parastatal	Services/Centers	GHP-State	0
	Health Agency		for Disease		
			Control and		
			Prevention		
		Other USG			_
12971	U.S. Peace Corps	Agency	U.S. Peace Corps	GHP-State	0
			U.S. Agency for		
13319	Futures Group	Private Contractor		GHP-USAID	0
			Development		
			U.S. Department		
			of Health and		
	African Field		Human		
13335		NGO	Services/Centers	GHP-State	0
	Network		for Disease		-
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	National Alliance		Human		
13534	of State and	NGO	Services/Centers	GHP-State	250,000
	Territorial AIDS		for Disease		,
	Directors		Control and		
			Prevention		
			U.S. Department		
			of Health and		
		Host Country	Human		
13593	SURINAME MOH	-	Services/Centers	GHP-State	1
		Agency	for Disease		
			Control and		
	1	1	1	1	1



16482	Population Services International	NGO	U.S. Department of Defense	GHP-State	0
16661	Caribbean Regional Public Health Agency	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	366,938
17366	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	1,674,565
17469	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-USAID	675,000
17760	FHI 360	NGO	U.S. Agency for International Development	GHP-State	845,000
17808	TBD	TBD	Redacted	Redacted	Redacted
17809	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-USAID	350,000
17810	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-USAID	0
17878	US Embassies	Other USG Agency	U.S. Agency for International Development	GHP-State	85,010
17902	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	710,000
17919	African Society for	NGO	U.S. Department	GHP-State	0



	Laboratory		of Health and		
	Medicine		Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
17921	University of	University	Services/Health	GHP-State	2,008,000
	Washington		Resources and		
			Services		
			Administration		
	Partnership for		U.S. Agency for		
18183	Supply Chain	Private Contractor	International	GHP-USAID	0
	Management		Development		
	U.S. Department				
18184	of Defense	Other USG	U.S. Department	GHP-State	0
	(Defense)	Agency	of Defense		
			U.S. Department		
			of Health and		
	Davis Memorial		Human		
18185	Hospital and	FBO	Services/Centers	GHP-State	0
	Clinic		for Disease		
			Control and		
			Prevention		
10400		Other USG			
18186	U.S. Peace Corps	Agency	U.S. Peace Corps	GHP-State	0
			U.S. Agency for		
18187	John Snow Inc		International	GHP-USAID	1,000,000
	(JSI)	Agency	Development		
			U.S. Department		
	Caribbean		of Health and		
18188	Regional Public	Parastatal	Human	GHP-State	0
	Health Agency		Services/Centers		
			for Disease		



			Control and		
			Prevention		
18189	TBD	TBD	Redacted	Redacted	Redacted
18190	Ministry of Health, Guyana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18392	Barbados MOH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1
18393	Bahamas MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	270,000
18394	Trinidad MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1
18395	TBD	TBD	Redacted	Redacted	Redacted
18396	Caribbean Regional Public Health Agency	Parastatal	U.S. Department of Health and Human Services/Centers	GHP-State	369,000

Custom 2017-04-11 10:08 EDT Page 226 of 335

FACTS Info v3.8.21.10



			for Disease Control and Prevention		
18398	Global Data Analysis and Technical Assistance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	545,157
18405	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,262,000
18406	TBD	TBD	Redacted	Redacted	Redacted
18427	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	1,233,936



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 12542	Mechanism Name: University of California, San Francisco (UCSF-SITAC) CoAg GH000977
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San	Francisco
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount	
Jamaica	100,000	
Suriname	125,000	
Trinidad and Tobago	50,000	
Guyana	0	

Total All Funding Sources: 300,000		
Applied Pipeline Amount: 50,000		
Total All Funding Sources and A		
Managing Country Funding Source		Funding Amount
Barbados	GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	5,000	
Focus Area:	Equity in HIV prevention, care, treatment and	
	support	
Sub Area:	Collection and Use of Gender-related Strategic	
	Information	



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: FSW	20,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	250,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners

Mechanism ID:	12542			
Mechanism Name:	University of California, San Francisco (UCSF-SITAC) CoAg GH000977			
Prime Partner Name:	University of California at San Francisco			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HVSI	300,000	0	

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12567	Mechanism Name: Jamaica MOH
Funding Agency: USAID	Procurement Type: Grant



Prime Partner Name: Jamaica Ministry of Health (MOH)		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
G2G: Yes Managing Agency: USAID		

Benefiting Country	Benefiting Country Planned Amount	
Jamaica	0	

Total All Funding Sources: 3,105,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
3,105,000		
Managing Country Funding Source		Funding Amount
Jamaica	GHP-State	3,105,000

Key Populations: MSM and TG	1,500,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	750,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention



Focus Area:	Training of health workers and community outreach	
	workers	
	Collection and use of strategic information on SWs	
	and clients	
Focus Area:	Monitoring and evaluation of SW programs	

Mechanism ID: 12567			
Mechanism Name:	e: Jamaica MOH		
Prime Partner Name:	Jamaica Ministry of Hea	alth (MOH)	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,775,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	280,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	145,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	800,000	0

Implementing Mechanism Indicator Information



OU	Indicator Number	Label	2017
Jamaica	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,909
Jamaica	KP_PREV_DSD	Total estimated number of key population in the catchment area	31,807
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,092
Jamaica	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	817
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	18,190
Jamaica	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	13,617
Jamaica	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,717
Jamaica	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	982



		1	
Jamaica	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	735
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,717
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,717
Jamaica	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	98
Jamaica	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	22
Jamaica	HTC_TST_DSD	Service Delivery Point (Community): Other	1,717
Jamaica	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,728
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,108
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	6,620
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,728
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,728
Jamaica	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,220
Jamaica	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	585
Jamaica	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	635
Jamaica	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,220
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	770
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	377
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	393
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	770
Jamaica	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	4,575
Jamaica	INVS_COMD	Number of HIV Test Kits purchased	1,889



Jamaica	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,343
Jamaica	INVS_COMD	Number of HIV ARVs purchased	1,343
Jamaica	INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	10,198
Jamaica	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	80,580
Jamaica	INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	161,160

Implementing Mechanism Details

Mechanism ID: 12570	Mechanism Name: Bahamas MOH	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Bahamas MoH		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: Yes	Managing Agency: HHS/CDC	

Benefiting Country	Benefiting Country Planned Amount	
Bahamas	0	

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID: Mechanism Name:			
Prime Partner Name:	Bahamas MoH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,333
Bahamas	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,333
Bahamas	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	40,000

Mechanism ID: 12575	Mechanism Name: PAHO/PHCO Cooperative AgreementCK000346	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Pan American Health Organiza	ation (PAHO)/PAHO HIV Caribbean Office (PHCO)	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country		Benefiting C	Country Planned Amount
Custom		Page 235 of 335	EACTS Info v3 8 21 10



Barbados	350,000
Guyana	0

Total All Funding Sources: 350,000		
Applied Pipeline Amount: 150,00		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	350,000

Key Populations: FSW	50,000
Focus Area:	Collection and use of strategic information on SWs
	and clients
Key Populations: MSM and TG	50,000
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	PAHO/PHCO Cooperative AgreementCK000346 Pan American Health Organization (PAHO)/PAHO HIV Caribbean Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	115,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	235,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12587	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/WHA	Procurement Type: Grant
Prime Partner Name: US Embassies	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 200,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 200,000		
Managing Country Funding Source		Funding Amount
Bahamas	GHP-State	30,000



Barbados	GHP-State	50,000
Jamaica	GHP-State	60,000
Suriname	GHP-State	30,000
Trinidad and Tobago	GHP-State	30,000

Key Populations: MSM and TG	100,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current
	PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Gender: GBV	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic

Budget Code Information

Mechanism ID:	12587		
Mechanism Name:	PEPFAR Small Grants Program		
Prime Partner Name:	US Embassies		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVOP	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Custom 2017-04-11 10:08 EDT



Mechanism ID: 12588	Mechanism Name: CARICOM/PANCAP
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Caribbean Community (CARIC	OM) Pan Caribbean Partnership Against AIDS
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0
Guyana	0

Total All Funding Sources 200,000	:	
Applied Pipeline Amount:	0	
Total All Funding Sources	and Applied Pipeline Amount:	200,000
Managing Country Funding Source		Funding Amount
Barbados	GHP-USAID	200,000

Gender: GBV	50,000



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Human Resources for Health	50,000
Key Populations: FSW	50,000
Focus Area:	Collection and use of strategic information on SWs
	and clients
Key Populations: MSM and TG	50,000
Focus Area:	Collection and use of strategic information

Mechanism ID: Mechanism Name: Prime Partner Name:	CARICOM/PANCAP Caribbean Community (CARICOM) Pan Caribbean Partnership Against				
Strategic Area	Budget Code Planned Amount On Hold Amount				
Care	НВНС	70,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVCT	30,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVOP	30,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Treatment	HTXS	70,000	0		

Implementing Mechanism Indicator Information

(No data provided.)

Custom 2017-04-11 10:08 EDT



Implementing Mechanism Details

Mechanism ID: 12594	Mechanism Name: SI Regional Training
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: HRM	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	2,083
Antigua and Barbuda	2,084
Bahamas	2,084
Barbados	2,084
Dominica	2,084
Grenada	2,083
Guyana	2,083
St. Kitts and Nevis	2,083
St. Lucia	2,083
St. Vincent and the Grenadines	2,083
Suriname	2,083
Trinidad and Tobago	2,083

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

Key Populations: FSW

0

Custom



Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	0
Focus Area:	Monitoring and evaluation of MSM/TG programs

Mechanism ID: Mechanism Name: Prime Partner Name:	SI Regional Training		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12606	Mechanism Name: Barbados MOH CoAg GH000637
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Barbados MOH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Barbados	0



Applied Pipeline Amount: 199,99		
Total All Funding Sources and A		
Managing Country Funding Source		Funding Amount
Barbados	0	

(No data provided.)

Budget Code Information

Mechanism ID: 12606					
Mechanism Name: Barbados MOH CoAg GH000637					
Prime Partner Name:	_				
Strategic Area	Budget Code Planned Amount On Hold Amount				
Care	HBHC	0	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and Systems	HLAB	0	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and Systems	HVSI	0	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and Systems	OHSS	0	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVCT	0	0		



Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Barbados	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	500
Barbados	INVS_COMD	Number of HIV Viral Load Reagents purchased	500
Barbados	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	25,000

Implementing Mechanism Details

Mechanism ID: 12642	Mechanism Name: Central Laboratory Support	
Funding Agency: HHS/CDC	Procurement Type: Contract	
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and		
Prevention (HHS/CDC)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country		Benefiting Country Planned Amount	
Jamaica		0	
Total All Funding Sources: 0			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Managing Country	Funding Source		Funding Amount

GHP-State

Barbados

0

Approved



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Central Laboratory Support U.S. Department of Health and Human Services/Centers for Disease		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12645	Mechanism Name: Caribbean HIV Grants, Solicitation and Management Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Jamaica	0

Total All Funding Sources: 0		
Custom	Page 245 of 335	FACTS Info v3.8.21.10
2017-04-11 10:08 EDT		



Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country Funding Source		Funding Amount
Jamaica	0	

(No data provided.)

Budget Code Information

Mechanism ID:	12645		
Mechanism Name:	Caribbean HIV Grants, Solicitation and Management Project		
Prime Partner Name:	ame: World Learning		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12668	Mechanism Name: Trinidad and Tobago MOH (PS003108)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Trinidad MoH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC



Total All Funding Sources: 0		
Applied Pipeline Amount: 199,99		
Total All Funding Sources and Applied Pipeline Amount: 199,999		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

(No data provided.)

Budget Code Information

Mechanism ID:	12668		
Mechanism Name:	Trinidad and Tobago MOH (PS003108)		
Prime Partner Name:	Trinidad MoH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Trinidad and Tobago	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	882
Trinidad and Tobago	INVS_COMD	Number of HIV Viral Load Reagents purchased	882
Trinidad and Tobago	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	30,000

Custom 2017-04-11 10:08 EDT



Implementing Mechanism Details

Mechanism ID: 12688	Mechanism Name: CARPHA REPDU (formerly CHRC Caribbean Health Research Council	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Caribbean Regional Public Health Agency		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12688 Mechanism Name: CARPHA REPDU (formerly CHRC Caribbean Health Research Council Prime Partner Name: Caribbean Regional Public Health Agency



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12971	Mechanism Name: HVOP -Prevention	
Funding Agency: PC	Procurement Type: USG Core	
Prime Partner Name: U.S. Peace Corps		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A	pplied Pipeline Amount: 0	
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID:	12971		
Mechanism Name:	HVOP - Prevention		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 13319	Mechanism Name: Health Policy Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Futures Group		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country Funding Source		Funding Amount
Barbados	GHP-USAID	0

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Health Policy Project		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 13335	Mechanism Name: Regional Laboratory Accreditation		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: African Field Epidemiology Network			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A	pplied Pipeline Amount: 0	
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

(No data provided.)

Budget Code Information

Mechanism ID:	13335			
Mechanism Name:	Regional Laboratory Accreditation			
Prime Partner Name:	African Field Epidemiology Network			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	0	0	



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13534	Mechanism Name: NASTAD CoAg GH001508
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and	Territorial AIDS Directors
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Trinidad and Tobago	250,000
Guyana	0

Total All Funding Sources: 250,000		
Applied Pipeline Amount: 100,00		
Total All Funding Sources and A		
Managing Country Funding Source		Funding Amount
Barbados	GHP-State	250,000

Key Populations: FSW	150,000
Focus Area:	Collection and use of strategic information on SWs
	and clients
Focus Area:	Conducting epidemiologic, social science, and
	operational research among SWs, their partners,
	and clients



Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	100,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

	NASTAD CoAg GH001508		
Strategic Area	National Alliance of State and Territorial AIDS Directors Budget Code Planned Amount On Hold Amount		
Governance and Systems	HVSI	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 13593	Mechanism Name: Suriname MOH CoAg GH000640
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SURINAME MOH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC



Benefiting Country Benefiting Country Planned Amo	
Barbados	1
Total All Funding Sourcess 4	

Total All Funding Sources: 1				
Applied Pipeline Amount: 194,999				
Total All Funding Sources and A				
Managing Country	Funding Source	Funding Amount		
Barbados	GHP-State	1		

Key Populations: MSM and TG	1	
Focus Area:	Collection and use of strategic information	
	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners	
Focus Area:	Monitoring and evaluation of MSM/TG programs	

Budget Code Information

Mechanism Name:	Mechanism ID: 13593 Mechanism Name: Suriname MOH CoAg GH000640 Prime Partner Name: SURINAME MOH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Suriname	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	288
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	144
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	144
Suriname	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	288
Suriname	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,034
Suriname	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,034
Suriname	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	30,000

Mechanism ID: 16482	Mechanism Name: PSI Caribbean
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Suriname	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 400,00		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

(No data provided.)

Budget Code Information

Mechanism ID:	16482		
Mechanism Name:	PSI Caribbean		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Custom 2017-04-11 10:08 EDT



OU	Indicator Number	Label	2017
Suriname	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	805
Suriname	KP_PREV_DSD	Total estimated number of key population in the catchment area	5,160
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	315
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	490
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	4,000
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,160
Suriname	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	255
Suriname	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	95



	PERMISSION ONLY: 15+ Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	160
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	255
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	255
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	10
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	8
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	255
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	95
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	85
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	95
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	95
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	4
HTC_TST_TA	Service Delivery Point (Facility): VCT	95
	HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA	HTC_TST_DSDAggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ FemaleHTC_TST_DSDSum of Aggregated Age/Sex 15+HTC_TST_DSDSum of Aggregated Age/Sex disaggregatesHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ MaleHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_DSDService Delivery Point (Community): Mobile testingHTC_TST_TANumber of individuals who received T&C services for HIV and received their test results during the past 12 monthsHTC_TST_TAAggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ MaleHTC_TST_TAAggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ FemaleHTC_TST_TASum of Aggregated Age/Sex 15+HTC_TST_TASum of Aggregated Age/Sex disaggregatesHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ MaleHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ MaleHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ Female

Mechanism ID: 16661	Mechanism Name: CARPHA support CoAg GH001205
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Caribbean Regional Public Hea	alth Agency
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	3,000
Bahamas	45,000
Barbados	45,000
Dominica	3,000
Grenada	3,000
Jamaica	146,000
St. Kitts and Nevis	3,000
St. Lucia	3,000
Suriname	45,500
Trinidad and Tobago	65,438
St. Vincent and the Grenadines	5,000

Total All Funding Sources 366,938	::	
Applied Pipeline Amount:	0	
Total All Funding Sources	and Applied Pipeline Amount:	366,938
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	366,938

Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Human Resources for Health	50,000



Key Populations: MSM and TG	25,000
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

	16661 CARPHA support CoAg GH001205 Caribbean Regional Public Health Agency			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HLAB	56,680	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	310,258	0	

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17366	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country		Benefiting Country Planned Amount	
Custom	Page 26	1 of 335	FACTS Info v3.8.21.10
2017-04-11 10:08 EDT			



Bahamas	0
Barbados	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 1,674,565		
Applied Pipeline Amount: 1,000,		
Total All Funding Sources and A 2,675,100	pplied Pipeline Amount:	
Managing Country	Funding Amount	
Barbados	GHP-USAID	1,674,565

Key Populations: MSM and TG	360,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	240,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach



	workers
	WUIKEIS
Focus Area:	Collection and use of strategic information on SWs
	and clients
Focus Area:	Conducting epidemiologic, social science, and
	operational research among SWs, their partners,
	and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other
	commodities essential to core HIV services for SWs
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Mechanism ID: Mechanism Name: Prime Partner Name:	Linkages		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	502,370	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	167,455	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	251,185	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	251,185	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	502,370	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,102
Bahamas	KP_PREV_DSD	Total estimated number of key population in the catchment area	4,409
Bahamas	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	372
Bahamas	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	730



		required)	
Bahamas	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,489
Bahamas	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,920
Bahamas	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	882
Bahamas	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	294
Bahamas	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	588
Bahamas	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	882
Bahamas	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	882
Bahamas	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	18
Bahamas	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	30
Bahamas	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	48
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	18
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	30
Bahamas	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	48
Suriname	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	540



		1	
Suriname	KP_PREV_DSD	Total estimated number of key population in the catchment area	4,100
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	280
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	260
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,800
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,300
Suriname	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	432
Suriname	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	224
Suriname	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	208
Suriname	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	432
Suriname	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	432
Suriname	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	13



Suriname	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	10
Suriname	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	23
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	13
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	10
Suriname	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	23
Trinidad and Tobago	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,000
Trinidad and Tobago	KP_PREV_DSD	Total estimated number of key population in the catchment area	17,444
Trinidad and Tobago	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	400
Trinidad and Tobago	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	600
Trinidad and Tobago	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	6,616
Trinidad and Tobago	KP_PREV_DSD	By key population type: Female sex	10,828



			1
		workers (FSW) (Denominator: Total	
		estimated number of key population in the	
		catchment area)	
		Number of individuals who received T&C	
Trinidad and Tobago	HTC_TST_TA	services for HIV and received their test	600
		results during the past 12 months	
Trinidad and Tobago	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	360
Trinidad and Tobago	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	240
Trinidad and Tobago	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	600
Trinidad and Tobago	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	600
Trinidad and Tobago	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	22
Trinidad and Tobago	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	12
Trinidad and Tobago	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	36
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	23
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	13
Trinidad and Tobago	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	36

Mechanism ID: 17469	Mechanism Name: Health Finance and Governance
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0
Suriname	0
Trinidad and Tobago	0
Guyana	0

Total All Funding Sources: 675,000 Applied Pipeline Amount: 0		
Total All Funding Sources and A	pplied Pipeline Amount: 675,000	
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	675,000

(No data provided.)

Budget Code Information

Mechanism ID:	17469		
Mechanism Name:	Health Finance and Governance		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	675,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17760	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0

Total All Funding Sources: 845,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and A	pplied Pipeline Amount: 845,000	
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	845,000

Key Populations: MSM and TG	845,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other



commodities essential to core HIV services for
MSM/TG

Mechanism ID: Mechanism Name:	Linkages		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	625,000	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	145,000	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	75,000	(

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Jamaica	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	176
Jamaica	KP_PREV_DSD	Total estimated number of key population in the catchment area	564
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations	176



		reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	564
Jamaica	KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	118
Jamaica	KP_PREV_TA	Total estimated number of key population in the catchment area	376
Jamaica	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	118
Jamaica	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	376
Jamaica	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	142
Jamaica	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	142
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	142
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	142
Jamaica	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	22



Jamaica	HTC_TST_DSD	Service Delivery Point (Community): Other	82
Jamaica	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	94
Jamaica	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	94
Jamaica	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	94
Jamaica	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	94
Jamaica	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	14
Jamaica	HTC_TST_TA	Service Delivery Point (Community): Other	14
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	22
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	22
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	22

Implementing Mechanism Details

Mechanism ID: 17808	TBD: Yes
REDACTED	

Mechanism ID: 17809	Mechanism Name: Knowledge for Health II	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Johns Hopkins University Center for Communication Programs		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0



Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0
Guyana	0

Total All Funding Sources: 350,000		
Applied Pipeline Amount: 0		
Total All Funding Sources a	nd Applied Pipeline Amount: 3	50,000
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	350,000

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Human Resources for Health	50,000
Key Populations: FSW	100,000
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	100,000
Focus Area:	Collection and use of strategic information



Mechanism ID: 17809			
	Knowledge for Health II		
Prime Partner Name:	Johns Hopkins Univers	ity Center for Communica	ation Programs
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	122,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	52,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	52,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	122,500	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17810	Mechanism Name: Grant Management Solutions	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Management Sciences for Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A	pplied Pipeline Amount: 0	
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	0

(No data provided.)

Budget Code Information

Mechanism ID:	17810		
Mechanism Name:	Grant Management Solutions		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Approved



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17878	Mechanism Name: Quarterly Consultation Meetings
Funding Agency: USAID	Procurement Type: USG Core
Prime Partner Name: US Embassies	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 85,010		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 85,010		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	85,010

Key Populations: MSM and TG	34,000
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	20,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation

Mechanism ID:	17878		
Mechanism Name:	Quarterly Consultation Meetings		
Prime Partner Name:	US Embassies		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVOP	85,010	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17902	Mechanism Name: Health Policy Plus
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country		Benefiting	Country Planned Amount
Jamaica		0	
	[
Total All Funding Sources:			
710,000			
Applied Pipeline Amount: 0			
Total All Funding Sources and A	pplied Pipeline A	Mount: 710,000	
Managing Country	Funding Source		Funding Amount
Jamaica	GHP-State		710,000

Key Populations: MSM and TG	360,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	180,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Budget Code Information

Mechanism ID:	17902		
Mechanism Name:	Health Policy Plus		
Prime Partner Name:	Palladium Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care HBHC 710.000

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17919	Mechanism Name: HIV Rapid Testing Quality Improvement Initiative (RTQII)		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: African Society for Laboratory Medicine			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0
Suriname	0
Trinidad and Tobago	0
Antigua and Barbuda	0
Barbados	0
Dominica	0
Grenada	0
Guyana	0
St. Kitts and Nevis	0
St. Lucia	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount

Approved



Barbados	GHP-State	0
Baibauus	GITF-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17919			
Mechanism Name:	HIV Rapid Testing Quality Improvement Initiative (RTQII)			
Prime Partner Name:	Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
Bahamas	LAB_PT_TA	CD4: Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	Early infant diagnostics: Number of	1



[
		laboratories that participate in this PT program	
Bahamas	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
Bahamas	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	4
Bahamas	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	4
Bahamas	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Bahamas	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1
Bahamas	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Bahamas	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT	0



		program	
Bahamas	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Bahamas	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Bahamas	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Bahamas	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
Barbados	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	CD4: Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
Barbados	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5



Barbados	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	5
Barbados	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Barbados	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Culture/DST): Number of	0

Custom 2017-04-11 10:08 EDT Page 284 of 335

FACTS Info v3.8.21.10



		laboratories that perform this testing	
Jamaica	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
Jamaica	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	4
Jamaica	LAB_PT_TA	CD4: Number of laboratories that perform this testing	4
Jamaica	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Jamaica	LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
Jamaica	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Jamaica	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	18
Jamaica	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	18
Jamaica	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	18
Jamaica	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Jamaica	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Jamaica	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Jamaica	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable	6



		successful passing criteria in this PT program	
Jamaica	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	6
Jamaica	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	6
Jamaica	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Jamaica	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
Suriname	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Suriname	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
Suriname	LAB_PT_TA	CD4: Number of laboratories that perform this testing	1
Suriname	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT	1



		program	
Suriname	LAB_PT_TA	program Early infant diagnostics: Number of laboratories that participate in this PT program	1
Suriname	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Suriname	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
Suriname	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	8
Suriname	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	8
Suriname	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Suriname	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Suriname	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Suriname	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
Suriname	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	3
Suriname	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	3
Suriname	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0



Suriname	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Suriname	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Suriname	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Suriname	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Suriname	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
Trinidad and Tobago	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
Trinidad and Tobago	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	4
Trinidad and Tobago	LAB_PT_TA	CD4: Number of laboratories that perform this testing	4
Trinidad and Tobago	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Trinidad and Tobago	LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
Trinidad and Tobago	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Trinidad and Tobago	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
Trinidad and Tobago	LAB_PT_TA	HIV serologic/diagnostic testing: Number of	9

Custom 2017-04-11 10:08 EDT Page 288 of 335

FACTS Info v3.8.21.10



		laboratories that participate in this PT	
		program	
Trinidad and Tobago	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	9
Trinidad and Tobago	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Trinidad and Tobago	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Trinidad and Tobago	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	6
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	6
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT	0



		program	
Trinidad and Tabaga		TB diagnostics (Culture/DST): Number of	0
Trinidad and Tobago	LAB_PT_TA	laboratories that perform this testing	0

Implementing Mechanism Details

Mechanism ID: 17921	Mechanism Name: International AIDS Education and Training Center		
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement		
Prime Partner Name: University of Washington			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Benefiting Country	Benefiting Country Planned Amount
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 2,008,000		
Applied Pipeline Amount: 0		
Total All Funding Sources ar 2,008,000		
Managing Country	Funding Amount	
Barbados	GHP-State	2,008,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health 50,065



Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	International AIDS Education and Training Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HBHC	288,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	50,065	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	1,669,935	0	

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Barbados	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,578
Barbados	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	899
Barbados	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	679
Barbados	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,578
Barbados	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,578
Barbados	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	38
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	22
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	16
Barbados	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	38

Custom 2017-04-11 10:08 EDT



Barbados	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,262
Barbados	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,578
Barbados	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	719
Barbados	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	543
Barbados	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	899
Barbados	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	679
Jamaica	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,728
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,109
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	6,619
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,728
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,728
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,337
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,619
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,718
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	3,337
Jamaica	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	10,181



		laboratory results within the past 12	
		months.	
Jamaica	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,728
Jamaica	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	4,886
Jamaica	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	5,295
Jamaica	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	6,109
Jamaica	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	6,619
Jamaica	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	6
Suriname	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	464
Suriname	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	231
Suriname	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	233
Suriname	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	464
Suriname	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	464
Suriname	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	55
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	27
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	28
Suriname	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	55
Suriname	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the	325



Гг			
		medical records and /or supporting laboratory results within the past 12 months.	
Suriname	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	464
Suriname	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	162
Suriname	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	163
Suriname	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	231
Suriname	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	233
Suriname	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2
Trinidad and Tobago	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,291
Trinidad and Tobago	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	645
Trinidad and Tobago	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	646
Trinidad and Tobago	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,291
Trinidad and Tobago	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,291
Trinidad and Tobago	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	133
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	66
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	67
Trinidad and Tobago	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	133
Trinidad and Tobago	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results	1,162



		(<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
Trinidad and Tobago	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,291
Trinidad and Tobago	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	581
Trinidad and Tobago	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	581
Trinidad and Tobago	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	645
Trinidad and Tobago	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	646
Trinidad and Tobago	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	4

Mechanism ID: 18183	Mechanism Name: The Partnership for Supply Chain Management	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Partnership for Supply Chain Management		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0



Guyana	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A	pplied Pipeline Amount: 0	
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	0

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name:	18183 The Partnership for Sup	oply Chain Management	
Prime Partner Name:	Partnership for Supply Chain Management		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 18184	Mechanism Name: DoD Mech Guyana	
Funding Agency: DOD	Procurement Type: USG Core	
Prime Partner Name: U.S. Department of Defense (Defense)		



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Guyana	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 33,000		
Total All Funding Sources and Applied Pipeline Amount: 33,000		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0

(No data provided.)

Budget Code Information

Mechanism ID:	18184		
Mechanism Name:	DoD Mech Guyana		
Prime Partner Name:	U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Prevention HVOP 0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18185	Mechanism Name: Positively United to Support Humanity	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Davis Memorial Hospital and Clinic		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Guyana	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and A	pplied Pipeline Amount: 0	
Managing Country Funding Source		Funding Amount
Guyana	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18185



Mechanism Name: Prime Partner Name:				
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HBHC	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	MTCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	0	0	

Implementing Mechanism Indicator Information

Custom 2017-04-11 10:08 EDT



OU	Indicator Number	Label	2017
Guyana	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,955
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	71
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	745
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	67
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,072
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex <15	138
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,817
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,955
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	38
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	3
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	34
Guyana	HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,655
Guyana	HTC_TST_DSD	Service Delivery Point (Facility): Index testing	300
Guyana	TB_SCREENDX_DS D	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,718
Guyana	TB_SCREENDX_DS D	Screened for TB by Age/Sex:<15 Male	9
Guyana	TB_SCREENDX_DS D	Screened for TB by Age/Sex: 15+ Male	644
Guyana	TB_SCREENDX_DS	Screened for TB by Age/Sex:<15 Female	35

Custom 2017-04-11 10:08 EDT Page 300 of 335

FACTS Info v3.8.21.10



	D		
Guyana	TB_SCREENDX_DS D	Screened for TB by Age/Sex: 15+ Female	1,030
Guyana	TB_SCREENDX_DS D	Screen Result: Screened Positive for TB	35
Guyana	TB_SCREENDX_DS D	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	35
Guyana	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	27
Guyana	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8
Guyana	PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	38
Guyana	PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	2
Guyana	PMTCT_EID_TA	Sum of Infant Age disaggregates	40
Guyana	PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
Guyana	PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
Guyana	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,718
Guyana	TX_CURR_DSD	Aggregated Age/Sex: <15 Male	9
Guyana	TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	644
Guyana	TX_CURR_DSD	Aggregated Age/Sex: <15 Female	35
Guyana	TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,030
Guyana	TX_CURR_DSD	Sum of Aggregated Age/Sex <15	44
Guyana	TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,674
Guyana	TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,718
Guyana	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	322
Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2

Custom 2017-04-11 10:08 EDT



Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	147
Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2
Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	171
Guyana	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	322
Guyana	TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,160
Guyana	TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,546
Guyana	TX_PVLS_DSD	Numerator: Indication: Routine	1,160
Guyana	TX_PVLS_DSD	Denominator: Indication: Routine	1,546
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	29
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	543
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	29
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	559
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	38
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	715
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	40
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	753
Guyana	TX_RET_DSD	Number of adults and children who are still	151



			1
		alive and on treatment at 12 months after initiating ART	
Guyana	TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	178
Guyana	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
Guyana	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
Guyana	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
Guyana	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
Guyana	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
Guyana	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	76



		lost to follow-up)	
		Aggregated Age/Sex: <15 Female	
		(Denominator: Total number of adults and	
		children who initiated ART in the 12 months	
Guyana	TX_RET_DSD	prior to the beginning of the reporting	10
		period, including those who have died,	
		those who have stopped ART, and those	
		lost to follow-up)	
		Aggregated Age/Sex: 15+ Female	
		(Denominator: Total number of adults and	
		children who initiated ART in the 12 months	
Guyana	TX_RET_DSD	prior to the beginning of the reporting	84
		period, including those who have died,	
		those who have stopped ART, and those	
		lost to follow-up)	

Mechanism ID: 18186	Mechanism Name: Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Guyana	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 39,000		
Total All Funding Sources and Applied Pipeline Amount: 39,000		
Managing Country Funding Source		Funding Amount
Guyana	GHP-State	0

Approved



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

saaget eeae mierm			
Mechanism ID:	18186		
Mechanism Name:	Peace Corps		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 18187	Mechanism Name: Advancing Partners and Communities Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount



Guyana	0	
Total All Funding Sources: 1,000,000		
Applied Pipeline Amount: 300,0	00	
Total All Funding Sources and A 1,300,000	Applied Pipeline Amount:	
Managing Country	Funding Source	Funding Amount
Guyana	GHP-USAID	1,000,000

Croco Cutting Budget / turibution	
Key Populations: MSM and TG	160,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	130,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	18187			
Mechanism Name:	Mechanism Name: Advancing Partners and Communities Project			
Prime Partner Name:	John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HBHC	405,080	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HKID	97,193	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	100,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	152,449	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	



Prevention	HVOP	71,673	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	173,605	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Guyana	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,652
Guyana	KP_PREV_DSD	Total estimated number of key population in the catchment area	3,658
Guyana	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,286
Guyana	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,366
Guyana	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,837



Guyana	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total	1,821
		estimated number of key population in the catchment area)	
Guyana	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,652
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,274
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,360
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,634
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,652
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	61
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	67
Guyana	HTC_TST_DSD	Service Delivery Point (Community): Index testing	150
Guyana	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	1,739
Guyana	HTC_TST_DSD	Service Delivery Point (Community): Other	763
Guyana	OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	162



Guyana	OVC_SERV_DSD	Age/Sex: 18+ Male	52
Guyana	OVC_SERV_DSD	Age/Sex: 18+ Female	83
Guyana	OVC_SERV_DSD	Sum of Age/Sex disaggregates	135
Guyana	OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	12
Guyana	OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	15

Implementing Mechanism Details

Mechanism ID: 18188	Mechanism Name: CARPHA Guyana CoAg GH001642	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Caribbean Regional Public Health Agency		
reement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0		
Applied Pipeline Amount: 250,00		
Total All Funding Sources and Applied Pipeline Amount: 250,000		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18188		
Mechanism Name:	CARPHA Guyana CoAg GH001642		
Prime Partner Name:	Caribbean Regional Public Health Agency		
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18189	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 18190	Mechanism Name: Ministry of Health, Guyana CoAg GH001632	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health, Guyana		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 0		
Applied Pipeline Amount: 500,00	0	
Total All Funding Sources and A	pplied Pipeline Amount: 500,000	
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Ministry of Health, Guyana CoAg GH001632		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Guyana	TB_SCREENDX_TA	The number of PLHIV who were screened	1,861



		for TB symptoms at the last clinical visit at a	
		HIV facility during the reporting period.	
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	100
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	837
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	94
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	830
Guyana	TB_SCREENDX_TA	Screen Results: Screened Positive for TB	38
Guyana	TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	38
Guyana	TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	29
Guyana	TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	9
Guyana	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,861
Guyana	TX_CURR_TA	Aggregated Age/Sex: <15 Male	94
Guyana	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	830
Guyana	TX_CURR_TA	Aggregated Age/Sex: <15 Female	100
Guyana	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	837
Guyana	TX_CURR_TA	Sum of Aggregated Age/Sex <15	194
Guyana	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,667
Guyana	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,861
Guyana	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	349
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	2
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	163
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	2
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	182



Guyana	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	349
Guyana	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,256
Guyana	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,675
Guyana	TX_PVLS_TA	Numerator: Indication: Routine	1,256
Guyana	TX_PVLS_TA	Denominator: Indication: Routine	1,675
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	51
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	549
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	73
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	583
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	77
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	745
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	91
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	762
Guyana	TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	200
Guyana	TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	227



		stopped ART, and those lost to follow-up	
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	95
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	14



		those who have stopped ART, and those lost to follow-up)	
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109

Implementing Mechanism Details

Mechanism ID: 18392	Mechanism Name: Barbados MOH FOA GH16-1610 (Follow-on to CoAg GH000637)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Barbados MOH		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: Yes	Managing Agency: HHS/CDC	

Benefiting Country	Benefiting Country Planned Amount
Barbados	1

Total All Funding Sources: 1		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country Funding Source		Funding Amount
Barbados	GHP-State	1

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18392 Mechanism Name: Barbados MOH FOA GH16-1610 (Follow-on to CoAg GH000637) Prime Partner Name: Barbados MOH			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Barbados	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	164
Barbados	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	82
Barbados	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	82



Barbados	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	164
Barbados	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	120
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	60
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	60
Barbados	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	120

Implementing Mechanism Details

Mechanism ID: 18393	Mechanism Name: Bahamas MOH FOA GH16-1609 (Follow-on to CoAg PS002934)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Bahamas MoH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Bahamas	270,000

Total All Funding Sources: 270,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 270,000		
Managing Country Funding Source		Funding Amount
Barbados	GHP-State	270,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	80,000
Focus Area:	Training of health workers and community outreach
	workers



Focus Area:	Implementation of core HIV prevention interventions
	for MSM/TG that are consistent with the current
	PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and
	operational research among MSM/TG and their sex
	partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other
	commodities essential to core HIV services for
	MSM/TG
Key Populations: FSW	80,000
Focus Area:	Implementation of core HIV prevention interventions
	for SWs consistent with PEPFAR guidance on
	sexual prevention
Focus Area:	Training of health workers and community outreach
	workers
Focus Area:	Collection and use of strategic information on SWs
	and clients
Focus Area:	Conducting epidemiologic, social science, and
	operational research among SWs, their partners,
	and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other
	commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID:	18393			
Mechanism Name:	Bahamas MOH FOA GH16-1609 (Follow-on to CoAg PS002934)			
Prime Partner Name:	Bahamas MoH			
Strategic Area	Budget Code Planned Amount On Hold Amount			



Care	НВНС	37,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	52,500	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	192
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	96
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	96
Bahamas	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	192

Mechanism ID: 18394	Mechanism Name: Trinidad and Tobago MOH FOA GH16-1608 (follow up to CoAg PS003108)		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Trinidad MoH			



Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: Yes	Managing Agency: HHS/CDC	

Benefiting Country	Benefiting Country Planned Amount	
Trinidad and Tobago	1	

Total All Funding Sources: 1		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	1

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name:	Trinidad and Tobago MOH FOA GH16-1608 (follow up to CoAg PS003108)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Trinidad and Tobago	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	555
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	285
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	270
Trinidad and Tobago	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	555

Mechanism ID: 18395	Mechanism Name: CDC Prevention FOA GH16-1607	
Funding Agency: HHS/CDC	Procurement Type: Umbrella Agreement	
Prime Partner Name: TBD		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: No	Managing Agency:	

	Benefiting Country		Benefiting Country	Planned Amount
Custom		Page 32	2 of 335	FACTS Info v3.8.21.10



Bahamas	1
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0
Guyana	0

Total All Funding Sources: 1		
Applied Pipeline Amount: 596,69		
Total All Funding Sources and A		
Managing Country	Funding Amount	
Barbados	GHP-State	1

(No data provided.)

Budget Code Information

	18395 CDC Prevention FOA GH16-1607		
Prime Partner Name: Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1	0



Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	108
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	80
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	26
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	106
Jamaica	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,724
Jamaica	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,724
Jamaica	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	50,000
Trinidad and Tobago	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	882
Trinidad and Tobago	INVS_COMD	Number of HIV Viral Load Reagents purchased	882
Trinidad and Tobago	INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	30,000

Mechanism ID: 18396	Mechanism Name: CARPHA REPDU FOA GH16-1611 (Follow-on to CoAg GH000688)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Caribbean Regional Public Health Agency	
Agreement Start Date: Redacted Agreement End Date: Redacted	



TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	4,000
Bahamas	25,000
Barbados	25,000
Dominica	4,000
Grenada	4,000
Jamaica	170,000
St. Kitts and Nevis	4,000
St. Lucia	4,000
St. Vincent and the Grenadines	4,000
Suriname	25,000
Trinidad and Tobago	100,000

Total All Funding Sources: 369,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 369,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	369,000

Key Populations: FSW	100,000	
Focus Area:	Collection and use of strategic information on SWs and clients	
Focus Area:	Monitoring and evaluation of SW programs	
Key Populations: MSM and TG	100,000	
Focus Area:	Collection and use of strategic information	
Focus Area:	Monitoring and evaluation of MSM/TG programs	



Budget Code Information

Mechanism ID:	18396			
Mechanism Name:	CARPHA REPDU FOA GH16-1611 (Follow-on to CoAg GH000688)			
Prime Partner Name:	Caribbean Regional Public Health Agency			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HVSI	369,000	0	

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 18398	Mechanism Name: GDATA	
Funding Agency: HHS/CDC Procurement Type: Contract		
Prime Partner Name: Global Data Analysis and Technical Assistance		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: Yes		
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Guyana	220,157
Barbados	325,000

Total All Funding Sources:		
545,157		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 545,157		

Approved



Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	220,157
Barbados	GHP-State	325,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18398			
Mechanism Name:	GDATA			
Prime Partner Name:	Prime Partner Name: Global Data Analysis and Technical Assistance			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and			0	

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 18405	Mechanism Name: HQ Lab FOA GH16-1689 (Follow on to AFENET CoAg PS 002728)			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: American Society of Clinical Pathology				
Agreement Start Date: Redacted Agreement End Date: Redacted				
TBD: No	New Mechanism: Yes			
G2G: No	Managing Agency:			



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	5,000
Barbados	80,000
Dominica	5,000
Grenada	5,000
Guyana	0
Jamaica	563,000
St. Kitts and Nevis	5,000
St. Lucia	5,000
St. Vincent and the Grenadines	5,000
Suriname	200,000
Trinidad and Tobago	389,000

Total All Funding Sources: 1,262,000				
Applied Pipeline Amount: 200,000				
Total All Funding Sources and A				
1,462,000				
Managing Country Funding Source		Funding Amount		
Barbados	GHP-State	1,262,000		

Gender: Gender Equality	100,000	
Focus Area:	Increase gender-equitable access to income and	
	productive resources, including education	
Sub Area:	Capacity building	
Human Resources for Health	100,000	

Budget Code Information

-



	18405 HQ Lab FOA GH16-1689 (Follow on to AFENET CoAg PS 002728) American Society of Clinical Pathology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,262,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18406	TBD: Yes	
REDACTED		

Mechanism ID: 18427	Mechanism Name: Global Health Supply Chain Program		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: Global Health Supply Chain Program			
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: Yes		
G2G: No	Managing Agency:		

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0
Bahamas	0
Barbados	0
Suriname	0
Trinidad and Tobago	0



Total All Funding Sources: 1,233,936		
Applied Pipeline Amount: 2	266,064	
Total All Funding Sources a 1,500,000	and Applied Pipeline Amount:	
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	100,000
Guyana	GHP-USAID	226,787
Barbados	GHP-USAID	226,788
Suriname	GHP-USAID	226,786
Trinidad and Tobago	GHP-USAID	226,787
Bahamas	GHP-USAID	226,788

(No data provided.)

Budget Code Information

Mechanism ID:	18427			
Mechanism Name:	Global Health Supply Chain Program			
Prime Partner Name:	ime Partner Name: Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	1,233,936	0	

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services			110,119	50,408	110,119	160,527
ICASS			287,157	124,268	287,157	411,425
Management Meetings/Profes sional Development			145,966	129,928	145,966	275,894
Non-ICASS Administrative Costs			35,694	16,646	35,694	52,340
Staff Program Travel			155,344	143,192	155,344	298,536
USG Staff Salaries and Benefits - Internationally Recruited			210,443	108,971	210,443	319,414
USG Staff Salaries and Benefits - Locally Recruited			558,404	781,242	558,404	1,339,646
Total	0	0	1,503,127	1,354,655	1,503,127	2,857,782



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		5,000	0	5,000
ICASS		0		45,000	0	45,000
Indirect Costs		0		20,000	0	20,000
Institutional Contractors				35,000	0	35,000
Management Meetings/Profes sional Development		0		10,000	0	10,000
Staff Program Travel		0		75,000	0	75,000
USG Staff Salaries and Benefits - Locally Recruited		0		175,000	0	175,000
Total	0	0	0	365,000	0	365,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing GAP GHP-Sta	e GHP-USAID Applied Pipeline	Total	Total All Cost of
-------------------------------------	------------------------------	-------	----------------------



Business						Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing	9,900	336,231		15,694	346,131	361,825
Computers/IT Services	30,000	30,000		0	60,000	60,000
ICASS	72,175	633,400		114,425	705,575	820,000
Institutional Contractors		458,000		0	458,000	458,000
Management Meetings/Profes sional Development	4,701	79,100		7,453	83,801	91,254
Non-ICASS Administrative Costs	7,343	29,025		11,641	36,368	48,009
Staff Program Travel	27,632	246,800		43,808	274,432	318,240
USG Staff Salaries and Benefits - Internationally Recruited	1,018,750	416,499		0	1,435,249	1,435,249
USG Staff Salaries and Benefits - Locally Recruited	83,249	746,557		131,979	829,806	961,785
Total	1,253,750	2,975,612	0	325,000	4,229,362	4,554,362



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		0		9,650	0	9,650
Management Meetings/Profes sional Development		0		12,785	0	12,785
Staff Program Travel		0		12,786	0	12,786
USG Staff Salaries and Benefits - Internationally Recruited		399,544		0	399,544	399,544
USG Staff Salaries and Benefits - Locally Recruited		0		59,741	0	59,741
Total	0	399,544	0	94,962	399,544	494,506

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business
-------------------------------------	-----	-----------	-----------	---------------------	-------	---

Custom

Page 334 of 335

FACTS Info v3.8.21.10



						Categories and Applied Pipeline Amount
Non-ICASS Administrative Costs		0		2,000	0	2,000
Peace Corps Volunteer Costs		0		68,587	0	68,587
Staff Program Travel		0		10,000	0	10,000
Total	0	0	0	80,587	0	80,587